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1I.
I.
INTRODUCTION
It is likely that the famed expedition of Meriwether Lewis and William Clark would not have gone down
in the annals of history as such an overwhelming success1 without the use of what is now termed \dietary
supplements." The restorative powers of various plants and herbs they discovered along their journey, as
well as the natural medicines used by the native Indian tribes that they met and befriended, likely nourished
the bedraggled expedition party back to health on a number of occasions.2 Plants and herbs have long been
a source of food and medicine, and almost all cultures developed some type of folk medicine tradition from
these naturally-occurring substances;3 healers versed in the therapeutic properties of these items essentially
acted as physicians.4 In some countries today, physicians continue to incorporate traditional knowledge into
their medical practices and continue to prescribe herbal medicines as treatments.5 Similarly, as the science
of modern nutrition evolved and individual vitamins and nutrients were isolated, people began to investigate
the health benets of these substances and their eects on the body.
1Lewis and Clark's Corps of Discovery only lost one man during the entire journey. This death could not have been prevented,
as it was likely caused by appendicitis, which would have been a fatal condition during this time and was beyond the scope of
medical knowledge. See Stephen E. Ambrose, Undaunted Courage: Meriwether Lewis, Thomas Jefferson, and the
Opening of the American West (1996); The Journals of Lewis and Clark (Bernard DeVoto, ed. 1953).
2See generally Stephen E. Ambrose, Undaunted Courage: Meriwether Lewis, Thomas Jefferson, and the Opening
of the American West (1996); The Journals of Lewis and Clark (Bernard DeVoto, ed. 1953).
3See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 671 (1997).
4See Leticia M. Diaz, First St. John's Wort, Now SAM-e: Is Society as a Whole at Risk Without FDA Regulation of
Psychiatric Self-Medication, 9 Kansas J.L. & Pub. Pol'y 279 (Winter 1999).
5See Leticia M. Diaz, First St. John's Wort, Now SAM-e: Is Society as a Whole at Risk Without FDA Regulation of
Psychiatric Self-Medication, 9 Kansas J.L. & Pub. Pol'y 279 (Winter 1999). For example, eighty percent of physicians in
Germany prescribe herbal remedies, which total 12 percent of all prescriptions. See id.
2As emerging science enabled the development of food and drug regulation to ensure the distribution of
products that were safe, pure, and eective, debates began to rage about how to appropriately regulate
vitamins, nutrients, and other substances that could readily be classied as neither food nor drugs, yet
demonstrated some of the nutritive or therapeutic properties of both categories of substances. So began what
one jurist has termed a \bitter battle"6 between the Food and Drug Administration (\FDA"), the regulatory
agency established to ensure safe and truthfully represented products, and the dietary supplement industry.7
Legislative changes, court decisions, agency regulations, and public lobbying have provided the backdrop
for the tumultuous changes in the FDA's authority and in the way dietary supplements are perceived and
regulated. The stakes in this tug-of-war are high. Regulators, courts, and legislators must balance the
protection of the more than 50 percent of the American population who regularly use supplements with the
freedom of choice these consumers want, represented by a $31 billion dollar market for supplements and
related foods in 1999.8 In 1994, the debate reached a pivotal moment, as Congress passed a sweeping piece
of legislation, the Dietary Supplement Health and Education Act, which dramatically redened the approach
to regulating dietary supplements. Yet contentious issues still remain as the FDA and the industry test the
boundaries of this legislation. The regulation of claims that dietary supplement labels may bear remains a
particularly controversial and ambiguous problem. Partially due to the erosion of distinctions between food,
drugs, and dietary supplements, this issue has proved to be one on which it is extremely dicult for the
industry and the regulators to reach an equilibrium.
6National Nutritional Foods Association v. Kennedy, 572 F.2d 377, 379 (2nd Cir. 1978).
7See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 671 (1997).
8Analysts project that this market will greatly increase within the next ten years. See United States General Accounting
Office, Food Safety: Improvements Needed in Overseeing the Safety of Dietary Supplements and \Functional
Foods" (July 2000).
3II.
HISTORY OF DIETARY SUPPLEMENT REGULATION
Early Food and Drug Laws
American colonists \brought with them the tradition of food regulation established in England."9 State
governments began to regulate food and drugs in colonial times,10 primarily to address basic consumer
protection and trade concerns. For example, in 1785 the Commonwealth of Massachusetts responded to
the problem of tainted quinine being supplied to soldiers by passing the United States' rst food safety
regulation.11 Other early laws included inspecting foods such as bread and exported sh, meat, and our, in
order to ensure prevent fraud, encourage international trade, and ensure \fair competition."12 These laws
were local eorts that were sporadic and rudimentary, yet slowly became more prevalent as urbanization led
to a growth in food commerce and as the safety of the food supply was increasingly questioned.13
The regulation of food and drugs remained largely a state and local eort throughout the 19th century.
Although Congress enacted a few statutes dealing with drugs, none of these laws was comprehensive and
dealt with the safety and eectiveness of drugs in general.14 Rather, such eorts were fairly limited in scope,
such as a 1813 act (later repealed) to ensure a safe supply of smallpox vaccine,15 and the Import Drugs Act
9Peter Barton Hutt, Government Regulation of the Integrity of the Food Supply, 4 Annual Review of Nutrition 1 (1984)
(reprinted in Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 3 (2nd ed. 1991)).
10Food and Drug Administration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA
Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>.
11Jennifer Kay Braman, Food for Sport of Faustian Bargain: Regulating Performance Enhancing Dietary Supplements, 47
Clev. St. L. Rev. 417, 420 (1999).
12Food and Drug Administration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA
Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>.
13See Peter Barton Hutt, Government Regulation of the Integrity of the Food Supply, 4 Annual Review of Nutrition 1
(1984) (reprinted in Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 3 (2nd ed. 1991)).
14See Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 7-8 (2nd ed. 1991)).
15See Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 7-8 (2nd ed. 1991)).
4of 1848, which established national customs laboratories to ensure that drug imports met trade industry
standards for purity and potency.16 Congress did not pass the rst federal food laws, which primarily dealt
with controlling the import or export of specic adulterated foods, until 1883.17 These national eorts at
food and drug regulation, however, were not comprehensive. Fraudulent, unsafe, ineective, and adulterated
food and drug products remained prevalent.18 Thousands of \patent" medicines were readily available from
so-called \snake-oil salesmen" and other medicine men. These medicines frequently contained narcotics such
as opium, morphine, heroin, and cocaine, claimed to cure every disease, contained no information about
ingredients on their labels, and frequently harmed unsuspecting and uninformed consumers.19
Towards the end of the 19th century, a variety of factors began to converge to advocate the creation of a
comprehensive, federal law. In the 1870s, a grassroots movement called The Pure Food Movement began
to push for a national law against food adulteration.20 Advances in scientic methods and thought began
to increase opportunities to detect food contamination.21 Frustrated food industry members complained of
adulterated products and that the increasing state and local regulations regarding food and drugs created
great disparity among food laws.22 Authors and publications began warning of the prevalence and dangers
of adulterated food and drugs, creating a \full-edged" public outcry by 1879.23 In addition, the U.S.
16Food and Drug Administration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA
Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>.
17See Peter Barton Hutt, Government Regulation of the Integrity of the Food Supply, 4 Annual Review of Nutrition 1
(1984) (reprinted in Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 4 (2nd ed. 1991)).
18See Food and Drug Administration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA
Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>.
19See Food and Drug Administration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA
Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>. Such quack medicines often had
colorful and misleading names such as \Kick-a-poo Indian Sagwa," \Warner's Safe Cure for Diabetes," and \Hamlin's Wizard
Oil." See id.
20See Food and Drug Administration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA
Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>.
21See Kelly Ann Kaczka, From Herbal Prozac to Mark McGwire's Tonic: How the Dietary Supplement Health and Education
Act Changed the Regulatory Landscape for Health Products, 16 J. Contemp. Health L. & Pol'y 463, 468 (2000).
22See Food and Drug Administration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA
Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>. One food packer at this time
griped, \As it is now, we have to manufacture dierently for every state." Id.
23See Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 8 (2nd ed. 1991)).
5Department of Agriculture Division of Chemistry, under the direction of Dr. Harvey Wiley,24 began to
investigate and publish reports regarding food adulteration.25
Pure Food and Drugs Act of 1906
Upton Sinclair's novel, The Jungle, which detailed shocking unsanitary conditions in Chicago stockyards,
perhaps was the nal encouragement to take action at a national level.26 Congress eventually passed the
Pure Food and Drugs Act of 1906,27 which broadly prohibited the misbranding or adulteration of food, from
tainted oysters28 to unregulated elixirs.29 Although this law represented a positive step, it had serious limi-
tations and failed to address many issues. For example, the 1906 Act neither made any specic provisions for
dietary supplements30 nor regulated the safety31 or eectiveness of drugs, other than establishing \minimal
standards for quality, purity, and strength."32
Federal Food, Drug, and Cosmetic Act of 1938
24Dr. Wiley was appointed Chief Chemist from 1883 through 1912. See Peter Barton Hutt & Richard A. Merrill,
Food and Drug Law 8 (2nd ed. 1991)). He is often referred to as the \Crusading Chemist" and the \Father of the Pure Food
and Drugs Act." Food and Drug Administration, Milestones in U.S. Food and Drug Law History, FDA Backgrounder,
May 3, 1999 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/>.
25See Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 9 (2nd ed. 1991)); Food and Drug Admin-
istration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA Consumer, June 1981 (visited
Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>. Dr. Wiley's investigations are perhaps best known for his work
with food preservatives, as this study involved human testing of various common preservatives on 12 volunteers, who were
dramatically dubbed the \poison squad." See id.
26See Food and Drug Administration, The Story of the Laws Behind the Labels: Part I: 1906 Food and Drugs Act, FDA
Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/history1.html>. On the same day as the Pure
Food and Drugs Act was passed, June 30, 1906, Congress also passed a far more rigorous federal meat inspection act.
27Pure Food and Drug Act of 1906, ch. 3915, 34 Stat. 768 (repealed 1938).
28See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History
and Analysis 9 (1996).
29Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>.
30See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History
and Analysis 9 (1996).
31Jennifer Kay Braman, Food for Sport of Faustian Bargain: Regulating Performance Enhancing Dietary Supplements, 47
Clev. St. L. Rev. 417, 419-20 (1999).
32Kelly Ann Kaczka, From Herbal Prozac to Mark McGwire's Tonic: How the Dietary Supplement Health and Education
Act Changed the Regulatory Landscape for Health Products, 16 J. Contemp. Health L. & Pol'y 463, 468 (2000).
6The limitations of the Food and Drugs Act of 1906 became apparent in the subsequent years. In the 1930s, at
the height of the New Deal, Congress began work on the Federal Food, Drug, and Cosmetic Act (\FDCA")
in an eort to expand federal protection to consumers and to cure the limitations of the 1906 Act.33 First
Lady Eleanor Roosevelt was one of the main advocates of the FDCA, and her personal appearances on
its behalf and the display of the dramatically named \Chamber of Horrors", a collection of fraudulent and
dangerous products, at post oces, helped to create grassroots support for the legislation.34 Further, the
public was inamed by the 1937 deaths of over 100 people, who were poisoned by \elixir of sulfanilamide."35
The ensuing comprehensive legislation focused primarily on drug safety and establishing food standards of
identity.36
The FDCA also established a category of foods \for special dietary use" for the rst time,37 and instituted
specic labeling requirements for these foods.38 Other than these labeling requirements, dietary supplements
could not be neatly categorized under the FDCA, as regulation of \product[s] containing a vitamin, depending
on the way it was marketed and labeled, could be a food, a drug, or both."39 As the FDCA had expanded
the denition of drug to include non-food40 \articles intended to aect the structure or any function of the
33See Food and Drug Administration, The Story of the Laws Behind the Labels: Part II: 1938 { The Federal Food, Drug,
and Cosmetic Act, FDA Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/histor1a.html>.
34See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History
and Analysis i (1996).
35Food and Drug Administration, The Story of the Laws Behind the Labels: Part II: 1938 { The Federal Food, Drug,
and Cosmetic Act, FDA Consumer, June 1981 (visited Feb. 16, 2001) <http://vm.cfsan.fda.gov/lrd/histor1a.html>. This
product was found to contain diethylene glycol, more commonly known as antifreeze. See Jennifer Kay Braman, Food for
Sport of Faustian Bargain: Regulating Performance Enhancing Dietary Supplements, 47 Clev. St. L. Rev. 417, 419 (1999).
Congress was also concerned with regulating diet aids, which were more delicately referred to at the time as \anti-fat" or
\slenderizing" products. See id.
36I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History and
Analysis i (1996).
37See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History
and Analysis i (1996). Subsequently, the FDA established labeling requirements for such foods, which remained eective until
1962. See Laura A.W. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA, 54 Food & Drug L.J. 623,
624 (1999).
38Federal Food, Drug, & Cosmetic Act, 21 U.S.C. x 343(j) (1995). (\A food shall deemed to be misbranded (j) [i]f it purports
to be or is represented for special dietary uses, unless its label bears such information concerning its vitamin, mineral, and
other dietary properties as the Secretary determines to be, and by regulations prescribes as, necessary in order fully to inform
purchasers as to its value for such uses.")
39See Kelly Ann Kaczka, From Herbal Prozac to Mark McGwire's Tonic: How the Dietary Supplement Health and Education
Act Changed the Regulatory Landscape for Health Products, 16 J. Contemp. Health L. & Pol'y 463, 469 (2000).
40The FDCA explicitly exempted food items from the denition of drug. Federal Food, Drug, and Cosmetic Act, 21 U.S.C.A.
7body of man or other animals,"41 the FDA began to use these provisions to classify and regulate dietary
supplements as drugs, based on claims made on supplement product labels or in literature.42 When using
such a classication, the FDA could subject dietary supplements to the more stringent drug provisions of
the FDCA, including detailed labeling, safety, and ecacy requirements.43
In 1940 and 1941, shortly after the enactment of the FDCA, the FDA promulgated regulations regarding
labeling requirements for dietary supplements and dietary foods.44 These regulations established quantitative
minimum daily requirements (\MDR") as the standard for individual vitamins, minerals, and nutrients.45
For the next twenty years or so, the FDA's dietary supplement regulations, including its enforcement of drug
provisions against supplements, were challenged in a series of court decisions. Primarily focusing on labeling
issues, these rulings began to establish the limits of the FDA's authority under the FDCA to regulate dietary
supplements.46
Food Additives Amendment of 1958
x 321(g)(1)(C) (1994).
41Federal Food, Drug, and Cosmetic Act, 21 U.S.C.A. x 321(g)(1)(C) (1994).
42See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History
and Analysis 9 (1996). Dietary supplements were often portrayed as having health or medicinal benets.
43Federal Food, Drug, and Cosmetic Act, 21 U.S.C.A. xx 352, 355 (1994). Regulating dietary supplements as drugs was
intended \to bring certain potentially dangerous products that had physiological eects unrelated to disease, within the regu-
latory authority of the FDA." Roseann B. Termini, Esq., Pharmanex v. Shalala: A Wake Up Call for Congress and a Not So
Bitter Pill for the FDA, 26 Ohio N.U. L. Rev. 269, 276-77 (2000) (quoting Bruce Schindler, Where There's Smoke There's
Fire: The Dangers of the Unregulated Dietary Supplement Industry, 42 N.Y.L. Sch. L. Rev. 261, 268 (1998)).
44See Commission on Dietary Supplement Labels, 1997 report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>.
45See Commission on Dietary Supplement Labels, 1997 report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>; Peter Barton Hutt & Richard A. Merrill, Food and Drug Law 212
(2nd ed. 1991)). These regulations set no maximum levels of vitamins, minerals, or nutrients that could be included in a
dietary supplement or other food for special dietary use.
46See Kordel v. United States, 335 U.S. 345 (1948); United States v. Urbuteit, 335 U.S. 355 (1948); United States v.
8 Cartons, Containing \Plantation `The Original' etc., Molasses," 103 F. Supp. 626 (W.D.N.Y. 1951); United States v.
...\Sterling Vinegar and Honey...," 338 F.2d 157 (2d Cir. 1964); United States v. An Article of Drug Consisting of 250 Jars,
etc. of U.S. Fancy Pure Honey, etc., 218 F. Supp. 208 (E.D. Mich 1963), a'd 344 F.2d 288 (6th Cir. 1965). See generally also
I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History and
Analysis 9-10 (1996).
8In 1958, concern over food safety spurred Congress to enact the rst major amendment to the FDCA. The
Food Additives Amendment47 shifted the burden of proving the safety of ingredients in food from the FDA
to manufacturers and marketers.48 Modifying the old process of introducing a product rst and requiring
the FDA to later prove that the product was unsafe, the new provisions essentially provided the FDA
with premarket approval of food additives.49 Food additives were broadly dened as \any substance, the
intended use of which results, or may reasonably be expected to result, directly or indirectly, in its becoming
a component or otherwise aecting the characteristics of food."50 As the FDA believed that the ingredients
incorporated into dietary supplements51 conformed to this denition, it began to regulate supplements that
were not generally recognized as safe (\GRAS") or sanctioned prior to 1958 as food additives.52 This
classication enabled the FDA to regulate dietary supplements in a more stringent manner than it regulated
conventional foods.53
In the 1960s and 1970s, the FDA attempted to revise its earlier regulations regarding dietary supplements
and foods for special dietary uses. Accordingly, it promulgated a series of proposed and nal regulations
throughout this time54 that addressed a variety of issues, including changing labeling requirements,55 re-
47Food Additives Amendments of 1958, Pub. L. No. 85-929 x 1, 72 Stat. 1784 (1958), codied at 21 U.S.C. x 301 et seq., 42
U.S.C. x 210.
4821 U.S.C. x 348.
4921 U.S.C. x 348.
5021 U.S.C. x 301(s).
51Ingredients included vitamins, minerals and similar nutritional substances in a variety of delivery forms such as table,
capsule, powder, or liquid. See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,692 (June 18, 1993).
52See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,692 (June 18, 1993); 21 U.S.C. xx 301(s), 348.
53At this time, the term \dietary supplement" primarily referred to vitamins and minerals. As many vitamins and minerals
are GRAS or prior-sanctioned, the Food Additives Amendment did not signicantly increase the FDA's authority to regulate
such items. The denition of dietary supplement, however, broadened over time to include other substances, such as amino
acids and herbs. Accordingly, as most dietary supplement ingredients today, other than vitamins and minerals, are not GRAS
or prior-sanctioned, the food additives provisions now have a much greater eect on the FDA's power to regulate supplement
products. See Mark V. Nadel, Associate Director, National and Public Health, General Accounting Office, FDA
Regulation of Dietary Supplements 3 (1993).
54See Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>; I. Scott Bass & Anthony L. Young, Dietary Supplement Health
and Education Act: A Legislative History and Analysis 11 (1996); see, e.g., 38 F.R. 20708-18, 20730-40 (August 2,
1973).
55Proposed label changes included requiring a disclaimer that refuted the \myths of nutrition" by indicating that the modern
9placing the MDR with the U.S. recommended daily allowance (RDA),56 and limiting the combinations of
vitamins and minerals that could be sold as dietary supplements.57 One such proposal, which was introduced
in 196258 and eventually published with modications as a nal regulation by the FDA on August 2, 1973,59
was to limit the potency of vitamins, minerals, and other nutrients to specic levels of the RDA.60 Dietary
supplements containing higher potency levels or involving unauthorized vitamin and mineral combinations
would be regulated as drugs,61 thereby holding manufacturers to a much higher standard, requiring ex-
pensive and time-consuming studies.62 Opposition from the public,63 the dietary supplement industry, and,
ultimately, Congress led to court challenges of the regulations64 and to the introduction of specic legislation
to address the issue.65
diet in general contained sucient vitamins and minerals, that there was little scientic evidence the use or specic or combina-
tions of dietary supplements were benecial, and that optimal nutrition did not require excessive doses of vitamins and minerals
in order to avoid clinical deciencies. See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of
Drug Claims and Freedom of Choice, 49 Fla. L. Rev. 663, 673-74 (1997); Commission on Dietary Supplement Labels,
1997 Report (visited Feb. 16, 2001) <http://www.health.gov/dietsupp/ch2.htm>.
56The RDA established both minimum and maximum daily levels of recognized nutrients for both children and adults.
See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative His-
tory and Analysis 11 (1996); Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>.
57See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative
History and Analysis 11 (1996); Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>.
5827 Fed. Reg. 5815 (proposed June 20, 1962).
5938 Fed. Reg. 20708-18, 20730-40 (Aug. 2, 1973) (codied at 21 C.F.R. s 125.1(h) and subsequently invalidated in National
Nutritional Food Association v. Food and Drug Administration, 504 F.2d 761 (2nd Cir. 1974).
60See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative His-
tory and Analysis 11 (1996); Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>. For example, most vitamins and minerals could not exceed 150% of the U.S.
RDA, while vitamin A's potency limit was 200% of the RDA and vitamin D's potency limit was 100% of the RDA.
61This regulation would be \even in the absence of any explicit drug claim by the manufacturer, because of the lack of any
nutritional need for a higher dose." Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug
Claims and Freedom of Choice, 49 Fla. L. Rev. 663, 673-74 (1997).
62See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative
History and Analysis 11 (1996); Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>.
63\Public opposition [] began to mount due to a perception that RDAs did not reect scientic advances regarding the benet
of various nutrients in maintaining human health." I. Scott Bass & Anthony L. Young, Dietary Supplement Health and
Education Act: A Legislative History and Analysis 11 (1996).
64See, e.g., National Nutritional Foods Association v. Food and Drug Administration, 504 F.2d 761 (2nd Cir. 1974) (generally
agreeing that the FDA's could protect consumers by limiting the combinations and dose levels of vitamins and minerals
(remanding this issue for further consideration), although nding that merely lacking nutritional usefulness was insucient to
alone classify dietary supplements as drugs).
65See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative
History and Analysis 11 (1996); Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>.
10The Proxmire Amendment of 1976
Following the publication of the aforementioned 1973 regulations by the FDA, \outraged"66 dietary supple-
ment manufacturers and consumers began to lobby Congress intensely to rein in the FDA.67 In response,
approximately seventy bills were introduced during a nine-month period in 1973, beginning a three-year
debate on the appropriate limits of FDA authority to regulate vitamins and minerals.68 So began what has
since then become an oft-repeated event, as lobbying against unpopular rules enacted by the FDA leads to
congressional action and often harsh repudiation69 of the FDA's proposed or nal regulations.70 Ultimately,
in 1976 Congress enacted the \Proxmire Amendment"71 and added section 411 to the FDCA.72 The lan-
guage of the Proxmire Amendment appears to be specically targeted to striking down the August 1973
regulations that limit the potency and possible vitamin and mineral combinations of dietary supplements,
and provided that the FDA:
66Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of Choice,
49 Fla. L. Rev. 663, 674 (1997).
67See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 674-75 (1997).
68See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History
and Analysis 12 (1996).
69During the oor debate on Senator Proxmire's bill, he castigated the FDA's regulation eorts:
What the FDA wants to do is to strike the views of its stable of orthodox nutritionists into `tablets,' and bring them down
from Mount Sinai where they will be used to regulate the rights of millions of Americans, who believe they are getting a lousy
diet, to take vitamins and minerals. The real issue is whether the FDA is going to play `God.'
121 Cong. Rec. 39,979 (1975) (statement of Senator William Proxmire) (reprinted in I. Scott Bass & Anthony L. Young,
Dietary Supplement Health and Education Act: A Legislative History and Analysis 12 (1996)). He further advocated,
\The Proxmire-Schweiker bill is clear. Provided a vitamin or mineral is safe and not mislabeled, the consumer should have the
same freedom of choice to buy it just as he may buy thousands of other food and beverages." 121 Cong. Rec. 2066 (1975)
(statement of Senator William Proxmire) (reprinted in I. Scott Bass & Anthony L. Young, Dietary Supplement Health
and Education Act: A Legislative History and Analysis 12 (1996)).
70As addressed later in this piece, this same chain of events seemingly occurred to instigate the passage of the Nutrition
Labeling and Education Act of 1990, the Dietary Supplement Act of 1992, and the Dietary Supplement Health and Education
Act of 1994.
71The amendment was named after Senator Proxmire, who was one of its sponsors. See I. Scott Bass & Anthony L.
Young, Dietary Supplement Health and Education Act: A Legislative History and Analysis 12 (1996).
72See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History
and Analysis 12 (1996); Pub. L. No. 94-278, 90 Stat. 401 (1976), codied at 21 U.S.C.
x 350 and later revised by the DSHEA.
11(A)...may not establish ...maximum limits on the potency of any synthetic or natural
vitamin or mineral;
(B)...may not classify any natural or synthetic vitamin or mineral (or combination thereof)
as a drug solely because it exceeds the level of potency which [the FDA] determines is
nutritionally rational or useful;
(C)...may not limit ...the combination or number of any synthetic or natural (i) vitamin,
(ii) mineral, or (iii) other ingredient of food.73
Despite the fact that the Proxmire Amendment prohibited the FDA from regulating vitamins or minerals as
drugs solely on the basis of high-potency doses, the FDA persisted in its eorts. In National Nutritional Foods
v. Mathews,74 the FDA attempted to impute therapeutic intent75 upon the manufacturer to sell as drugs
doses of vitamins A and D that exceeded the U.S. R.D.A. The government argued that as such doses had
no nutritional value and are potentially toxic, their widespread use by consumers for therapeutic purposes
evidenced intent of the manufacturer to market the vitamins as drugs.76 The Court of Appeals for the
Second Circuit rejected the FDA's argument and issued a ruling consistent with the Proxmire Amendment,
making further classication of dietary supplements as drugs dicult for the FDA.77
Nutrition Labeling and Education Act of 1990
In the years following the Proxmire Amendment, the FDA relaxed its enforcement eorts against dietary
supplements,78 which allowed the introduction of a signicant number of new dietary supplement products
74National Nutritional Foods v. Mathews, 557 F.2d 325 (2nd Cir. 1977).
75Under the FDCA, the manufacturer's intent is essential to the determination of whether a substance should be classied
as a drug. 21 U.S.C.A x 321(g) (1995).
76See National Nutritional Foods v. Mathews, 557 F.2d 325, 334 (2nd Cir. 1977).
77See National Nutritional Foods v. Mathews, 557 F.2d 325, 334 (2nd Cir. 1977) (\There was no evidence, however,
supporting the Commissioner's conclusion that, when sold at the regulated, i. e. prescription, levels, therapeutic usage of these
vitamins so far outweighed their use as dietary supplements, it showed an objective intent that these products were used in the
mitigation and cure of diseases. This claim furnished no contradiction to the charge that the FDA's regulations are arbitrary
and capricious and not in accordance with law."); Iona N. Kaiser, Dietary Supplements: Can the Law Control the Hype?, 37
Hous. L. Rev. 1249, 1254 (2000); Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug
Claims and Freedom of Choice, 49 Fla. L. Rev. 663, 675 (1997).
78In 1993, FDA ocials stated that the agency \has not systematically regulated the 1976 enactment of the Proxmire
amendment," as \this amendment and actions taken by the courts relative to cases on other dietary supplements presented by
12throughout the 1980s.79 Some of these new products were herbs and other remedies that had often been used
in traditional medicine, expanding the dietary supplement industry beyond its traditional realm of vitamins
and minerals.80 As supplement availability grew, consumer use also increased.81 This rise in consumer use
was also spurred in part by increasing recognition and documentation of the importance of nutrition and the
benets of dietary supplements;82 however, ready availability of supplements also allowed \o-label uses"
by consumers for therapeutic purposes suggested in magazine articles by other unregulated or unproven
sources.83 Further, during the mid-1980s food and dietary supplement manufacturers began to make health
claims on foods, despite lack of approval by the FDA of the claims through the traditional drug approval
channels.84 Although the FDA previously had not sanctioned such claims, it became more permissive and
did not bring many enforcement actions against such products as it attempted to reformulate its policy
regarding health claims on food.85
Prior to 1984, FDA policy was that a disease claim86 on a food item eectively rendered the food a drug
and made it subject to the new drug approval process.87 The FDA's change in position on health claims was
the FDA" discouraged them from such regulation of dietary products. Mark V. Nadel, Associate Director, National and
Public Health, General Accounting Office, FDA Regulation of Dietary Supplements 4 (1993).
79See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 676 (1997).
80See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 676 (1997). For example, items such as shark cartilage could now be found in health food stores.
See id.
81See S. Rep. No. 103-410, at 21 (1994).
82See S. Rep. No. 103-410, at 20 (1994).
83See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 676 (1997).
84See H.R. Rep. No. 101-538, at 8 (1990).
85See H.R. Rep. No. 101-538, at 8-9 (1990).
86Structure/function claims could not render a food item a drug as food was explicitly exempted from the structure/function
clause of the drug denition in the FDCA. See 21 U.S.C. x 321(g)(1)(C).
87See H.R. Rep. No. 101-538, at 8 (1990). Codied in 21 U.S.C. 321(g)(1)(B), the FDCA denes a drug, in part, as \articles
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of a disease in man." Further 1973 regulations
promulgated by the FDA provided \in part, that a food shall be deemed to be misbranded if its labeling represents, suggests, or
implies that the food, because of the presence or absence of certain dietary properties, is adequate or eective in the prevention,
cure, mitigation, or treatment of any disease or symptom." 56 Fed. Reg. 60,537, 60,637-38 (November 27, 1991) (referencing
38 Fed. Reg. 6950, 6951 (March 14, 1973), codied at 21 C.F.R. 101.9(i)(1)).
13due to an increasing recognition that \certain dietary patterns, including increasing or decreasing relative
intake of certain types of food, may help maintain health by decreasing the risk of developing specic health
problems, including chronic diseases that account for a large proportion of morbidity and mortality in the
United States."88 Accordingly, the FDA advocated in an advance notice of proposed rulemaking issued
in 1987 that \[t]he rapid growth of scientic and public interest in nutrition argues for recognition and
dissemination of such new knowledge, and food labels oer one appropriate vehicle for this dissemination....
In light of advances in current knowledge, [] the agency now believes that health-related messages, when
appropriately formulated for use on food labels and consistent with existing law and regulations, may provide
valuable information to health-conscious consumers."89 Under the new proposed regulations, health claims
that met four criteria for truthfulness and scientic validity did not require prior FDA approval and fell
within a \safe harbor" from enforcement actions.90 Expressing skepticism at the eectiveness of and ability
to isolate the importance of adding any single nutrient to the diet, the FDA warned, however, that although
they would apply the same proposed criteria to dietary supplements as food, it would be more dicult for
dietary supplements to satisfy these criteria.91
After publication of the 1987 proposal, the use of unsubstantiated health claims expanded,92 as food and
dietary supplement manufacturers used \abusive marketing practices" to sell their products and promised
remedies for a variety of conditions, ranging from obesity to gallstones.93 As there was no system to distin-
guish between genuine and unsubstantiated health claims, and as \consumers are ill-equipped to evaluate
the accuracy of health claims on their own, and therefore often fall prey to unprincipled sales tactics," the
8852 Fed. Reg. 28,843, 28,844 (August 4, 1987).
8952 Fed. Reg. 28,843, 28,844-45 (August 4, 1987).
9056 Fed. Reg. 60,537, 60,538 (November 27, 1991).
9152 Fed. Reg. 28,843, 28,846 (August 4, 1987).
92See David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food &
Drug L.J. 535, 535 (1999); 56 Fed. Reg. 60,537, 60,538 (November 27, 1991).
93See David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food &
Drug L.J. 535, 537 (1999).
14potential for consumer fraud grew.94
Partially in response to this \rising tide of unsubstantiated health claims,"95 and in an eort to \permit
health claims based on scientically valid information,"96 Congress nally took action.97 In 1990, Congress
responded to a lack of regulation regarding health claims and 11 years of relative inaction by the FDA
to improve and modernize labeling requirements98 by enacting the Nutrition Labeling and Education Act
(\NLEA").99 The NLEA specically addresses each of these concerns.
First, the NLEA provides for mandatory nutrition labeling for most food products \intended for human con-
sumption and is oered for sale."100 The Act requires that such food products be labeled with information
regarding the serving size of the product, the number of servings per container, the total number of calories
per serving, the total number of calories of fat per serving, and the amount provided per serving of at least
nine specic nutrients.101 The FDA has discretion to require the inclusion of any other vitamin, mineral, or
nutrient that the agency determines \will assist consumers in maintaining healthy dietary practices."102
The NLEA also gives the FDA broad authority with respect to health claims by establishing detailed re-
quirements regarding the types of claims that food labels could contain and the process the FDA should use
for regulating such claims. In so doing, the NLEA requires that dierent types of claims be held to dierent
94See David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food &
Drug L.J. 535, 537 (1999).
95David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food & Drug
L.J. 535, 535 (1999).
96David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food & Drug
L.J. 535, 537 (1999) (citing 136 Cong. Rec. H12953 (daily ed. Oct. 26, 1990)(remarks of Rep. Waxman); see also H.R. Rep.
No. 538, 101st Cong., 2d Sess. 7, reprinted in 1990 U.S.C.C.A.N. 3336, 3337).
97Congress's eorts were partially based on regulations (55 Fed. Reg. 5176 (February 13, 1990)) proposed by the FDA in
1990 to revise and supercede the earlier 1987 proposed regulations for health claims. The 1990 proposed regulations more
narrowly dened health claims on food. See 56 Fed. Reg. 60,537, 60,538 (November 27, 1991).
98H.R. Rep No. 101-538, at 8 (1990). Although the FDA had held regulatory proceedings regarding new labeling, it had not
issued proposed regulations. Id.
99Nutrition Labeling and Education Act of 1990, Pub. L. No. 101-535, 104 Stat. 2353 (1990), codied at 21 U.S.C. xx 301,
343. President Bush signed this Act into law on November 8, 1990. See 56 Fed. Reg. 60,537, 60,537 (November 27, 1991).
10021 U.S.C. x 343. Certain types of food, such as food sold in bulk containers, raw agricultural products and sh, and food
served in restaurants, are covered by slightly dierent requirements. See id.
10121 U.S.C. x 343.
10221 U.S.C. x 343.
15levels of regulation. Section 343(r)(1)(A) denes the rst, and most basic type of label claim, as one that
\characterizes the level of any nutrient" that is of the type expressly required to be on the food label, as
provided elsewhere in
16the NLEA. In general, such nutrient level claims
(i) may only be made if the characterization of the level made in the claim uses terms which
are dened in regulations []103
(ii) may not state the absence of the nutrient unless {
(I) the nutrient is usually present in the food [], or
(II) the Secretary by regulation permits such a statement on the basis of nding that
such a statement would assist consumers in maintaining health dietary practices and
the statement discloses that the nutrient is not usually present in the food
(vi) may not be made if [prohibited by regulation] because the claim is misleading in light
of the level of another nutrient in the food.104
Information merely noting the amount of vitamins or minerals in the food as a percentage of the recommended
daily requirement is not considered to be a nutrient claim.105 Further provisions for nutrient level claims
require, among other things, specic action if the food contains a nutrient that increases the risk of disease,
and address acceptable label claims specically with respect to the level of cholesterol, saturated fat, and
dietary ber in the product.106
The second type of label claim dened by the NLEA is one that goes beyond merely interpreting the level
of the nutrient in the product. Rather, this type of claim \characterizes the relationship of any nutrient
[that is of the type expressly required to be on the food label, as provided elsewhere in the NLEA] to a
disease or a health-related condition."107 These types of claims, which more directly express a cause and
eect relationship between a specic vitamin or nutrient and a physiological eect, correspondingly must
meet stricter requirements than mere nutrient level claims. Specically, disease or health claims may only
be authorized by regulations enacted by the FDA:108
10521 U.S.C. x 343(r)(2)(E).
10621 U.S.C. x 343(r)(2).
10721 U.S.C. x 343(r)(1)(B).
108In directing the FDA to enact regulations within 12 months to implement the NLEA, the statute specically requires the
FDA to consider regulations regarding whether claims regarding particular nutrients and diseases meet the requirements for
disease or health claims. The FDA was directed to assess the relationship between calcium and osteoporosis, dietary ber
17The Secretary shall promulgate regulations authorizing [disease and health claims] only if the
Secretary determines, based on the totality of publicly available scientic evidence (including
evidence from well-designed studies conducted in a manner which is consistent with generally
recognized scientic procedures and principles), that there is signicant scientic agreement,
among experts qualied by scientic training and experience to evaluate such claims, that
the claim is supported by such evidence.109
In brief, the disease or health claims on food products must meet a standard of \signicant scientic agree-
ment." The NLEA also prohibits claims for foods that contain (as determined by regulation) any nutrient
\in an amount which increases to persons in the general population the risk of a disease or health-related
condition which is diet related, taking into account the signicance of the food in the total daily diet," unless
such a claim would \assist consumers in maintaining health dietary practices."110 By creating this new cat-
egory of health claims for foods, Congress is eectively bypassing the drug approval process that otherwise
would govern foods labeled with what had previously been considered to be drug representations.111 Rather,
disease or health-related claims merely must receive premarket approval from the FDA and no longer must
worry about the rigorous drug approval regime.112
In order to implement the provisions of the NLEA, the statute requires the FDA to propose regulations
within one year that address what types of nutrient level, disease, and health claims are allowed.113 Further,
the NLEA establishes discrete timeframes in which the FDA must evaluate and rule on all petitions for
regulations { such as those supporting a specic nutrient and disease relationship or dening terms that
characterize nutrient levels { and all petitions for permission to associate nutrient characterization terms
with a given nutrient level claim.114 These provisions ensure that statute implementation and the premarket
and cancer, lipids and cardiovascular disease, lipids and cancer, sodium and hypertension, and dietary ber and cardiovascular
disease. Nutrition Labeling and Education Act of 1990 x 3(b)(1)(A)(vi).
11021 U.S.C. x 343(r)(3)(A)(ii).
111See Arnold I. Friede, Dietary Supplements: Background for Dialogue Between the Industry and the Medical Profession, 53
Food & Drug L.J. 413, 414 (1998).
112See Arnold I. Friede, Dietary Supplements: Background for Dialogue Between the Industry and the Medical Profession, 53
Food & Drug L.J. 413, 414 (1998).
113Nutrition Labeling and Education Act of 1990, x 3(b)(1)(A).
114For example, the FDA has 100 days after receipt of a petition for regulation to accept or deny the petition and 90 days after
submission of a petition to use specic nutrient characterization terms in a nutrient level claim to grant or deny permission.
See 21 U.S.C. x 343(r)(4)(A)(i).
18approval process for health claims will occur in a timely fashion.
Most of the language found in the NLEA expressly dealt with labels on food products; these provisions, by
extension, also opened the door to authorize the FDA to regulate claims made on dietary supplement labels,
as dietary supplements are merely a subset of food. Although the original bill did not include separate
provisions specically targeted towards the regulation of dietary supplement claims,115 such a clause was
later added and appeared in the nal statute.116 This key addition, which created a potential exception for
dietary supplements from the NLEA requirements regarding claims on food, is codied in 21 U.S.C., section
343(r)(5)(D), and provides that
[a] claim [that includes a statement regarding the relationship of any nutrient in the product
to a disease or health-related condition] made with respect to a dietary supplement of
vitamins, minerals, herbs, or other similar nutritional substances ...shall be subject to a
procedure and standard, respecting the validity of such claim, established by regulation of
the Secretary.117
The NLEA also directed the FDA to evaluate the validity of several relationships between particular vita-
mins, minerals, herbs and other nutritional substances and disease or health-related claims.118 Interpretation
of these provisions regarding health claims on dietary supplements generated considerable controversy. Some
argued that section 343(r)(5)(D) represented an invitation by Congress to the FDA to \craft a more per-
missive approach" to regulation of claims on supplements than regulation of claims on foods.119 Others
believed that by allowing the FDA to promulgate regulations that established a dierent approval process
115See H.R. Rep. No. 101-538, at 23 (1990).
116See 21 U.S.C. x 343.
118Nutrition Labeling and Education Act of 1990, x 3(b)(1)(A)(x). The FDA was directed to evaluate the relationship between
folic acid and neural tube defects, antioxidant vitamins and cancer, zinc and immune function in the elderly, and omega-3 fatty
acids and heart disease.
119I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History and
Analysis 17 (1996). For example, Senator Hatch stated,
By their very nature, the dietary supplement must be marketed so that the consumer is informed of the health or disease-
prevention benets that may be conferred. Greater exibility is thus required to permit communication of these benets.
This increased regulatory exibility is also mandated by the very rapid pace of scientic advances her and abroad linking the
prevention of long-term disease to improved nutritional supplementation. For these reasons, a more lenient standard for dietary
supplement[s] is envisioned.
56 Fed. Reg. 60,537, 60,540 (November 27, 1991) (citing Cong. Rec. S16611 (October 24, 1990) (statement of Sen. Hatch)).
19and scientic evaluation standard for health claims on dietary supplement labels, Congress was suggesting
that the standards and processes for supplements should be at least as restrictive and perhaps even more
restrictive than those set for food.120
As a result of this uncertainty, consumers feared that the implementation of this law would result in a denial
of access to dietary supplement products.121 On November 27, 1991, consumers and dietary supplement
manufacturers received their rst concrete notice of how the FDA intended to interpret and implement
the ambiguous provisions of the NLEA, as the FDA published proposed rules regarding the enactment of
the NLEA.122 Specically, the proposed rules did not take advantage of the purported leeway in section
343(r)(5)(D) and dene standards for regulating health claims on dietary supplements more leniently or
more strictly than the standards used for health claims on food.123 Rather, the FDA took the \middle road"
and proposed that health claims on dietary supplements and all other foods be held to the same scientic
standard.124 Such an approach, the FDA indicated, \strikes an appropriate balance between the desire to
make information available and the desire to ensure that information is truthful, usable, and not mislead-
120See David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food &
Drug L.J. 535, 537-38 (1999) (referencing 136 CONG. REC. H12953 (daily ed. Oct. 26, 1990) (statements of the House Floor
Managers of both parties that dietary supplements \covered by this provision should be subject to at least as strong a standard
as is applicable to other foods"); see also 136 CONG. REC. S16608 (daily ed Oct. 24, 1990) (statement of Sen. Metzenbaum,
sponsor of the bill)).
121See Jennifer Sardina, Misconceptions and Misleading Information Prevail { Less Regulation Does Not Mean Less Danger
to Consumers: Dangerous Herbal Weight Loss Products, 14 J.L. & Health 107, 116 (1999-2000). For example, consumers
\voiced concern that supplements would be removed from stores or only available with a doctor's prescription. FDA ocials
tried to dispel these false beliefs and reassure consumers that products would not be removed but relabeled if necessary." Id.
\These fears were \spurred on by some makers of dietary supplements who are waging an all-out campaign, with brochures
and handouts, telling consumers they can `kiss their supplements good-bye' if the FDA is given jurisdiction over them."" Id.,
at 116 n.81 (citing Kathi Gannon, Vitamin Showdown: Who Should Control Dietary Supplements?, Drug Topics, Jan. 24,
1994, available in 1994 WL 2886032).
122See 56 Fed. Reg. 60,537 (November 27, 1991).
123See 56 Fed. Reg. 60,537 (November 27, 1991).
124See 56 Fed. Reg. 60,537 (November 27, 1991). Although the FDA acknowledged that proposing the same standard runs
contrary to the opinions expressed by some members of Congress, it believed that the legislative history of the NLEA did
not require the FDA to promulgate dierent standards for dietary supplements, but rather authorized discretion to adopt any
appropriate scientic standard. Although statements of various members of Congress dier with respect to whether the FDA
should adopt stricter, more lenient, or the same standards for dietary supplements, most of such statements emphasize the
need for FDA exibility in this area. See id., at 60,540. Such exibility would allow the FDA to base its approach on the
considerations of \[p]ublic health, sound scientic principles, and consumer fraud." Id. (citing Cong. Rec. S16611 (October
24, 1990) (statement of Sen. Metzenbaum)).
20ing."125 Further, the FDA found that holding both dietary supplements and conventional food to the same
standards reects the idea that it is the nutrient content of the diet that is important, not the source of
the nutrient.126 These proposed regulations dened dietary supplements in fairly broad terms, moving away
from the more limited denition of supplements that the FDA had embraced in the past.127
Dietary Supplement Act of 1992
Many consumers, dietary supplement manufacturers, and other industry groups found these proposed regula-
tions to be unduly restrictive.128 Accordingly, these groups began to lobby Congress to stop implementation
of the NLEA at least, and possibly to repeal the whole act altogether.129 Congress listened and responded
to the lobbying eorts by passing the Dietary Supplement Act of 1992 (\DSA").130 Essentially, this Act
instituted a one-year moratorium on the implementation of the provisions of the NLEA that pertained to
dietary supplements.131 Specically, the DSA prohibits the FDA from implementing any provision of the
12556 Fed. Reg. 60,537, 60,540 (November 27, 1991).
126See 56 Fed. Reg. 60,537, 60,541-42 (November 27, 1991).
127See 56 Fed. Reg. 60,537, 60,542 (November 27, 1991). Under the new denition, a dietary supplement is considered to be
a food, \other than a conventional food, that supplies a component with nutritive value to supplement the diet by increasing
the total dietary intake of that substance," including \food for special dietary use[s] that is conventional food form." Id., at
60,542-43. Thus herbs and other nutritional substances that did not provide essential nutrients were now considered to be
supplements, although they had not been so considered previously. See id., at 60,543.
128See Jennifer Sardina, Misconceptions and Misleading Information Prevail { Less Regulation Does Not Mean Less Danger
to Consumers: Dangerous Herbal Weight Loss Products, 14 J.L. & Health 107, 116 (1999-2000); Iona N. Kaiser, Dietary
Supplements: Can the Law Control the Hype?, 37 Hous. L. Rev. 1249, 1259 (2000). One issue that manufacturers were
unhappy about was the amount of additional research that would be required for each new claim. See Iona N. Kaiser, Dietary
Supplements: Can the Law Control the Hype?, 37 Hous. L. Rev. 1249, 1259 (2000). The industry also cited several other
specic concerns, including the following items: requiring that health claims on supplements be subject to the same \signicant
scientic agreement" standard as food, especially in light of the FDA's earlier comments that it \had seen no scientic support
for supplement claims; treating herbs as lacking the baseline nutritive value required in order to bear a health claim; stripping
vitamins and minerals of their status as supplements if present in \therapeutic" rather than \nutritional" amounts; disallowing
several essential nutrients from being sold as supplements as they were \unsafe food additives"; and requiring full nutrition
labeling on certain supplement products. See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and
Education Act: A Legislative History and Analysis 18 (1996).
129See Jennifer Sardina, Misconceptions and Misleading Information Prevail { Less Regulation Does Not Mean Less Danger
to Consumers: Dangerous Herbal Weight Loss Products, 14 J.L. & Health 107, 116 (1999-2000); Iona N. Kaiser, Dietary
Supplements: Can the Law Control the Hype?, 37 Hous. L. Rev. 1249, 1259 (2000).
130Dietary Supplement Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491 (1992), codied at 21 U.S.C. xx 301, 343. President
Bush signed this Act into law on November 8, 1990. See 56 Fed. Reg. 60,537, 60,537 (November 27, 1991).
131See Dietary Supplement Act of 1992, x 202; Cong. Rec. S17239 (October 7, 1992).
21NLEA regarding dietary supplements prior to December 15, 1993.132 In the interim, the moratorium will
\provide time for the Congress, HHS, consumer groups, industry, and other aected parties to identify more
fully and to consider the public health issues associated with the use of dietary supplements, and to develop
a comprehensive approach for reforming the regulation of dietary supplements."133 To facilitate the exami-
nation of dietary supplements, the DSA also requires three separate analyses of dierent aspects of the issue
by government agencies.134
The 1992 Act thus gave a temporary reprieve to Congress from having to take a stand on the growing
controversy between dietary supplement manufacturers, consumers, and the FDA. Congress's decision to
punt the question of how supplements should be regulated was unsurprising, given the popular volatility
of the issue. In addition to debates over appropriate labeling, tensions were mounting due to a few other
factors. First, the dietary supplement market had changed signicantly in recent years, as consumer use
of supplements grew dramatically.135 These market variations were attributable to consumers' increasing
interest in the health benets of supplements,136 increasing advertising of certain products, and the growing
132See Dietary Supplement Act of 1992, x 202(a)(1). The FDA, however, must repropose regulations to enact these provisions
of the NLEA by June 15, 1993 and have nal regulations in place no later than December 31, 1993. See id., at x 202(a).
133Cong. Rec. S17239 (October 7, 1992). As a justication for this moratorium, Congress notes that the NLEA primarily
focused upon food products. As the use of dietary supplements and food products dier historically, \it is appropriate for
Congress to enact this moratorium so that the issue of how best to regulate dietary supplements may be carefully considered."
Id.
134Dietary Supplement Act of 1992, xx 204, 205. Under the Act, the FDA must prepare and submit a report within 30 days
detailing its \enforcement priorities and practices ...with respect to dietary supplements of vitamins, minerals, herbs, or other
similar nutritional substances." The Comptroller General was similarly required to conduct a study of the FDA's practices
regarding regulation and enforcement of dietary supplements; the Oce of Technology Assessment was commissioned a study
of whether and how other industrialized countries regulate dietary supplements and what eects such schemes have on health
outcomes. See id. These reports ultimately proved not to be very useful in analyzing the controversy and in shaping future
regulation; \none of these reports played an identiable role in the legislative discussions that followed." I. Scott Bass &
Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History and Analysis 21 (1996).
135Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690 (June 18, 1993). One report stated that \[a]n estimated 35
to 60 percent of the population use dietary supplements daily or occasionally, and up to 60 million users take supplements daily."
Mark V. Nadel, Associate Director, National and Public Health, General Accounting Office, FDA Regulation
of Dietary Supplements 4 (1993). Overall, more than 100 million Americans were at this time attempting to enhance their
diet through some sort of supplement product. See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690 (June 18,
1993). These estimates are perhaps a bit modest, as the statistics presented by Congress in support of the Dietary Supplement
Health and Education Act of 1994 suggest somewhat higher usage. See S. Rep. No. 103-410, at 5, 20-21 (1994).
136Although wide variation in usage was reported according to factors such as \age, lifestyle, socioeconomic status, and
geographic location," reasons commonly cited for using dietary supplements included \cultural and ethnic practices, perceived
health and nutritive eects including emotional and psychological needs, and perceived insurance against dietary insuciency."
Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690 (June 18, 1993).
22availability of dietary supplements through a variety of channels.137 Any attempt to impose restrictions on
these increasingly popular products would likely not be well received. Second, the FDA had been targeting
supplements for increased regulation for some time in response to signicant public safety concerns. In 1989,
use of L-tryptophan, a popular amino acid often used to treat insomnia or depression,138 resulted in at least
1,500139 cases of eosinophilia myalgia syndrome (EMS) and resulted in 38 deaths.140 This tragedy provoked
the agency141 to establish the Dietary Supplement Task Force in May 1991 to reevaluate the FDA's regu-
lations regarding dietary supplements, with a specic focus upon safety concerns.142 Finally, the ongoing
debate between the FDA and dietary supplement industry over the proper legal basis for regulation loomed
ominously behind the other controversies surrounding these products.143 In general, since Congress passed
the Food Additives Amendments in 1958,144 the FDA had considered dietary supplements to be food addi-
tives.145 Accordingly, it had used its authority granted under this amendment of the FDCA to ensure that
dietary supplements are safe and their labels are truthful and not misleading.146 Such regulation essentially
allowed the FDA to require premarket approval of supplements and placed the burden on supplement man-
137See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690 (June 18, 1993). In 1993, dietary supplements were
widely available at \grocery stores, drug stores, health food stores, and specialty nutrition stores, as well as by mail order." Id.
138See Mark V. Nadel, Associate Director, National and Public Health, General Accounting Office, FDA Reg-
ulation of Dietary Supplements 2 (1993).
139More than 1,500 cases were reported to and conrmed by the Centers for Disease Control and Prevention (CDC). One FDA
ocial indicated that these number are misleadingly low because the vast majority of illnesses attributable to L-tryptophan
were never reported; rather, she estimated that this supplement caused between 5,000 and 10,000 people to become ill. See
Mark V. Nadel, Associate Director, National and Public Health, General Accounting Office, FDA Regulation
of Dietary Supplements 2 n.1 (1993).
140See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690 (June 18, 1993).
141Although the L-tryptophan crisis undoubtedly galvanized the agency into action, it was not an isolated incident, as the FDA
also received reports of serious illnesses associated with other dietary supplements. See Regulation of Dietary Supplements, 58
Fed. Reg. 33,690, 33,690 (June 18, 1993).
142See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,691 (June 18, 1993).
143See Mark V. Nadel, Associate Director, National and Public Health, General Accounting Office, FDA Reg-
ulation of Dietary Supplements 3 (1993).
14421 U.S.C. x 348.
145See supra note 53. In practice, the FDA regulated dietary supplements as a food, a drug, or both depending on its intended
use. See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,692 (June 18, 1993) (\[I]ngredients incorporated into
dietary supplements (vitamins, minerals, amino acids, herbs, and other similar nutritional substances that are processed in
tablet, capsule, powder, or liquid form) are food additives unless they are [GRAS] or prior-sanctioned.")
146See Mark V. Nadel, Associate Director, National and Public Health, General Accounting Office, FDA Reg-
ulation of Dietary Supplements 4 (1993).
23ufacturers to establish product safety.147 In contrast, dietary supplement manufacturers believed that their
products should be regulated as food that is not subject to premarket approval.148
All of these issues played a role in formulating the FDA's regulatory approach to supplements. Pursuant
to Congress's order in the DSA, on June 18, 1993, the FDA published two sets of regulations regarding
dietary supplements.149 The rst notice was a proposed rule regarding appropriate labeling requirements
for dietary supplements. This proposed rule echoed many aspects of the FDA's proposed rule regarding
dietary supplements published in 1991. In essence, the agency recommended that nutrient claims, health
claims, and other labeling issues regarding dietary supplements be treated in much the same fashion as labels
on conventional foods.150 The second set of proposed regulations published at this time were much more
controversial, as they went further than merely addressing labeling issues.151 Rather, the FDA published a
comprehensive advance notice of proposed rulemaking (\ANPR") regarding the regulation of dietary sup-
plements in general, \in response to the Dietary Supplement Act of 1992 (the DS act), recent developments
and events in the marketplace, and the report of an outside expert body on the safety of amino acid supple-
147See Mark V. Nadel, Associate Director, National and Public Health, General Accounting Office, FDA Reg-
ulation of Dietary Supplements 4 (1993); Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,692 (June 18, 1993).
Certain vitamins and minerals were either generally recognized as safe (GRAS) or prior-sanctioned and thus not subject to
premarket review. This premarket review is generally not carried out with respect to dietary supplements. Rather, the FDA's
regulation of supplement products occurs more on a case-by-case basis as specic examples of safety concerns or misbranding
are brought to the agency's attention. See Mark V. Nadel, Associate Director, National and Public Health, General
Accounting Office, FDA Regulation of Dietary Supplements 4 (1993);
148See Mark V. Nadel, Associate Director, National and Public Health, General Accounting Office, FDA Reg-
ulation of Dietary Supplements 3 (1993).
149Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690 (proposed June 18, 1993) (to be codied at 21 C.F.R.
Ch.1); Food Labeling: Requirements for Nutrient Content Claims for Dietary Supplements of Vitamins, Minerals, Herbs, and
Other Similar Nutritional Substances, 58 Fed. Reg. 33,731 (proposed June 18, 1993) (to be codied at 21 C.F.R. x101).
150See Food Labeling: Requirements for Nutrient Content Claims for Dietary Supplements of Vitamins, Minerals, Herbs, and
Other Similar Nutritional Substances, 58 Fed. Reg. 33,731, 33,731-32 (June 18, 1993). Pursuant to the provisions of the NLEA,
the FDA promulgated nal regulations regarding nutrient content and health claims for conventional foods on January 6, 1993.
Final Rule on Nutrient Content Claims, 58 Fed. Reg. 2302 (January 6, 1993) (codied at 21 C.F.R. x 101). As the \FDA
[] tentatively concluded that it would be helpful to continue to minimize inconsistencies in nutrient content claims between
dietary supplements and foods in conventional food form," it proposed that \similar nutritional substances should generally
be subject to the same requirements as other foods." Food Labeling: Requirements for Nutrient Content Claims for Dietary
Supplements of Vitamins, Minerals, Herbs, and Other Similar Nutritional Substances, 58 Fed. Reg. 33,731, 33,731-32 (June
18, 1993). The agency conceded, however, that several sections of the regulations pertaining to conventional foods may require
revision to be applied appropriately to dietary supplements. Id., at 33,732.
151Regulation of Dietary Supplements, 58 Fed. Reg. 33,690 (June 18, 1993).
24ments."152 This notice incorporated the ndings of the Dietary Supplement Task Force, various meetings
with \industry, public health, and consumer group representatives,"153 and an independent expert body
contracted to evaluate the safety of amino acids after the L-tryptophan crisis.154 Based on this data, the
various provisions of the ANPR included, among other things, several suggestions about regulation of various
types of dietary supplements, primarily focusing on safety concerns.155 First, the ANPR recommended that
the FDA establish a maximum dosage level for vitamins and minerals due to toxicity concerns at high levels
of intake.156 Second, the FDA indicated that it intended to bring \into compliance with the law"157 many
amino acids currently on the market, as they are unapproved food additives and \adequate scientic evidence
to ensure their safe use does not exist."158 Further, due to their wide use and marketing for therapeutic
purposes, the ANPR proposed regulating amino acids as drugs.159 Third, the ANPR noted that many herbs
sold as supplements \have no known history of food use and, even without drug claims, are used for medical
purposes."160 Accordingly, the FDA proposed to remove hazardous herbs from the market and to bring
regulatory action against herbal products that are marketed for drug use.161
The proposed actions embodied in the June 1993 regulatory notices set o a maelstrom of controversy and
spurred considerable protest from both consumers and the dietary supplement industry.162 The regulations
152Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,690 (June 18, 1993).
153Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,691 (June 18, 1993).
154After the EMS outbreaks associated with L-tryptophan use, the FDA contracted with the Life Sciences Research Oce,
Federation of American Societies of Experimental Biology (LSRO/FASEB) to evaluate the safety of amino acids. See Regulation
of Dietary Supplements, 58 Fed. Reg. 33,690, 33,691 (June 18, 1993).
155See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,691 (June 18, 1993). Such safety concerns included both
\direct" and \indirect" hazards associated with supplement use. The FDA dened direct hazards as those \adverse health
eects directly attributable to the components of dietary supplement products," such the eect of a particular ingredient or
the presence of a contaminant. Indirect hazards, on the other hand, resulted when \the use of a supplement product delays
the diagnosis or treatment of a health disorder [such as when the product claims benets that are unfounded or exaggerated]."
Id., at 33,692.
156See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,694-95 (June 18, 1993).
157Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,697 (June 18, 1993).
158See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,697 (June 18, 1993).
159Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,697 (June 18, 1993).
160Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,697 (June 18, 1993). This medical use of many herbs may
stem from the fact that many herbs have historically and currently been used as traditional medicines in many countries. See
id., at 33,698.
161See Regulation of Dietary Supplements, 58 Fed. Reg. 33,690, 33,698 (June 18, 1993).
162See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
25were viewed as a warning that the FDA was going to restrict access to supplements severely, by removing
them from stores163 or by classifying them as drugs that required a prescription. Further, the regulations
were seen by many as an attempt to reinstate regulations that had been struck down by courts or specic
legislation.164 Dietary supplement manufacturers also saw the FDA's intention to hold label claims on di-
etary supplements to generally the same standards as label claims on food products as a warning of a harsher
regulatory regime.165 These concerns so inamed industry and consumer sentiment that dietary supplement
supporters organized a \National Blackout Day," during which supplement products \targeted" by the FDA
regulations were draped in black crepe paper to emphasize the potential impact of unfettered regulation
of supplements.166 The FDA Commissioner unsuccessfully attempted to assuage public concerns, but the
dramatic yet eective demonstration had already provoked a \public outcry" against the FDA.167
Dietary Supplement Health and Education Act of 1994
The dietary supplement industry and consumers168 began to lobby Congress heavily to restrict the FDA's
Choice, 49 Fla. L. Rev. 663, 678 (1997); Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>.
163For example, \[t]he application of the food additive provisions to amino acids, as suggested by the FDA Advance Notice,
would eectively remove many of these supplements from stores" absent scientic evidence of their safety. Margaret Gilhooley,
Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of Choice, 49 Fla. L. Rev. 663,
678 (1997).
164See Commission on Dietary Supplement Labels, 1997 Report (visited Feb. 16, 2001)
<http://www.health.gov/dietsupp/ch2.htm>. To illustrate, the restrictions proposed for \high-dosage" vitamins and
minerals are arguably analogous to the ones struck down by the courts in the 1970s and barred through the Proxmire
Amendment. The FDA's eorts to regulate dietary supplements as unsafe food additives have been similarly questioned by
courts. In 1993, two unanimous decisions by dierent courts of appeal dismissed the FDA's eorts to regulate black currant
oil as an unsafe food additive as \nonsensical" and as an \Alice in Wonderland" approach. Sen. Rep. No. 103-410, at 10-11
(1994) (referencing United States v. Two Plastic Drums, 984 F.2d 814 (7th Cir. 1993); United States v. 29 Cartons of ...an
Article of Food, 987 F.2d 33 (1st Cir. 1993)).
165See Iona N. Kaiser, Dietary Supplements: Can the Law Control the Hype?, 37 Hous. L. Rev. 1249, 1257-58 (2000).
166See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 678 (1997); Iona N. Kaiser, Dietary Supplements: Can the Law Control the Hype?, 37 Hous. L.
Rev. 1249, 1257-58 (2000).
167See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 678 (1997); Iona N. Kaiser, Dietary Supplements: Can the Law Control the Hype?, 37 Hous. L.
Rev. 1249, 1257-58 (2000).
168In this era of self-treatment and preventive health, many consumers preferred to make their own decision about products
rather than having the FDA ltering out the information that would be made available. See I. Scott Bass & Anthony L.
26regulatory authority over supplements and to prevent the FDA from nalizing the 1993 proposed regula-
tions.169 In the summer of 1993, Congress began to receive a tremendous volume of mail,170 telephone calls,
and constituent pressure to ensure access to dietary supplements.171 This overwhelming lobbying eort
continued in 1994, as \[m]any members of the House of Representatives and Senate stated that they were
receiving more [communications and demands] on this subject than on anything else { including health care
reform, abortion, or the decit."172
Once again, Congress responded to public and industry protests regarding unpopular FDA regulations by
passing legislation to amend the FDCA. On October 25, 1994, President Clinton signed into law the Dietary
Supplement Health and Education Act of 1994 (\DSHEA"),173 which was passed unanimously by both the
House of Representatives and the Senate.174 The DSHEA represents Congress's eorts to improve public
access to and information regarding safe dietary supplement products and to create a \rational Federal
framework" for supplement regulation to replace \the current ad hoc, patchwork regulatory policy".175 In
addition, the DSHEA recognizes that improving the health of Americans is a top priority and that mil-
Young, Dietary Supplement Health and Education Act: A Legislative History and Analysis i (1996).
169See David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food &
Drug L.J. 535, 538-39 (1999).
170\Later in 1993, Congressman Waxman, then chairman of the House Health Subcommittee of the Commerce Committee,
wrote to other members about `the large volume of mail on the issue of dietary supplements.' Waxman said much of the
mail was generated by scare tactics to lead the public to believe the FDA was about to take vitamins, herbs and other dietary
supplements o the market or to require prescriptions for them." William J. Skinner, R.Ph., J.D., Allowable Advertising Claims
for Dietary Supplements, 5 J. Pharmacy & L. 309, 314 (1996) (citing a letter from Congressman Henry Waxman, Chairman of
House Health Subcommittee of Committee to other members of Committee (Oct. 14, 1993) (reproduced at 55 Food & Drug
Report 737 (1994))).
171See William J. Skinner, R.Ph., J.D., Allowable Advertising Claims for Dietary Supplements, 5 J. Pharmacy & L. 309,
309 (1996); Stephen H. McNamara, FDA Regulation of Ingredients in Dietary Supplements After Passage of the Dietary
Supplement Health and Education Act of 1994: An Update, 51 Food & Drug L.J. 313, 313 (1996).
172Stephen H. McNamara, FDA Regulation of Ingredients in Dietary Supplements After Passage of the Dietary Supplement
Health and Education Act of 1994: An Update, 51 Food & Drug L.J. 313, 313 (1996). One observer suggested that the
dietary supplement lobbying campaign was \solely responsible for the purchase of many telephone answering machines" by
congressional oces. William J. Skinner, R.Ph., J.D., Allowable Advertising Claims for Dietary Supplements, 5 J. Pharmacy
& L. 309, 309 (1996).
173Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat. 4325 (1994), codied at 21 U.S.C.
x 301 et seq., 42 U.S.C. x 287.
174See Stephen H. McNamara, FDA Regulation of Ingredients in Dietary Supplements After Passage of the Dietary Supple-
ment Health and Education Act of 1994: An Update, 51 Food & Drug L.J. 313, 313 (1996). The House of Representatives
passed the DSHEA on October 7, 1994, and the Senate approved the measure on October 8, 1994. See id.
175Dietary Supplement Health and Education Act of 1994, Pub L. 103-417, 108 Stat. 4325, 4325-26 (1994).
27lions of Americans rely on use of dietary supplements as a preventive health measure.176 Accordingly, the
DSHEA nds that taking legislative action that protects access to safe preventive health measures will not
only empower consumers to make informed health choices but also extend lives while reducing individual
and national health care expenditures.177 In a harsh criticism of the FDA, Congress notes that the agency's
\heavy-handed enforcement agenda" against dietary supplements for decades despite a \voluminous scien-
tic record" supporting the health benets these supplements has \forced" Congress to intervene on several
occasions; the DSHEA is merely the latest in the series of such eorts.178 The DSHEA, however, is unique
in that it represents Congress's rst concrete foray into comprehensive regulation specically tailored to
concerns relating to the dietary supplement industry.179 In an interesting political move, sponsors of the
bill negotiated a \Statement of Agreement" to limit the legislative history of the DSHEA to ve stipulated
resolutions.180 This eort perhaps reected a need to present a united front on this controversial and bit-
terly fought battle between the industry and the FDA.181 The Statement of Agreement may also have been
a strategy to forestall the FDA \from seizing upon certain language to continue its eorts to invoke the most
stringent requirements possible."182
176Dietary Supplement Health and Education Act of 1994, x 2. The ndings of the DSHEA indicate that \almost 50 percent
of the 260,000,000 Americans regularly consume dietary supplements of vitamins, minerals, or herbs as a means of improving
their nutrition." Id.
177Dietary Supplement Health and Education Act of 1994, x 2. The economics of health care expenditures and the size of
the dietary supplement industry are somewhat staggering. In 1994, national health care costs totaled over one trillion dollars,
approximately 12 percent of the gross national product (\GNP"). Sales of dietary supplement products exceeded 4 billion dollars
in 1994. See id.
178S. Rep. No. 103-410, at 10 (1994).
179Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat. 4325 (1994), codied at 21 U.S.C.
x 301 et seq., 42 U.S.C. x 287. Previous Congressional interventions either were not specically targeted at dietary supplements,
such as the NLEA, or were not comprehensive in their scope, such as the Proxmire Amendment.
180140 Cong. Rec. S14801 (daily ed. Oct. 7, 1994).
181See William J. Skinner, R.Ph., J.D., Allowable Advertising Claims for Dietary Supplements, 5 J. Pharmacy & L. 309, 309
(1996). One \inside [] beltway political observer" even hypothesized that \the pent-up disgust with the Congress on this one
issue is just as likely a cause of the Democratic Party's downfall [in the November 1994 elections, in which Republicans gained
control for the rst time in 40 years] as was the `Contract with America."' Id.
182William J. Skinner, R.Ph., J.D., Allowable Advertising Claims for Dietary Supplements, 5 J. Pharmacy & L. 309, 309
(1996).
28Several of the key provisions of this comprehensive legislation are briey described below.
Denitions
The DSHEA attempted to clarify years of uncertainty by dening the term \dietary supplement" for the rst
time.183 This broad denition moved beyond the traditional notion that dietary supplements are merely
made up of vitamins, minerals, proteins, and other essential nutrients;184 rather, the new denition also
included herbs, amino acids, and other substances used to supplement the diet in its scope.185 Dietary
supplements must be clearly labeled as such,186 and may appear in conventional food form187 or as tablets,
capsules, powders, softgels, or liquids188 if they are \not represented for use as conventional food or as
a sole item of a meal or the diet."189 More importantly, the DSHEA specically conrms that products
meeting the new denition of dietary supplement should be regulated as food, not as drugs, provided that
the label does not make a prohibited disease claim.190 Products that are approved as drugs, licensed
183S. Rep. No. 103-410, at 22 (1994).
184See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 666 (1997).
185See 21 U.S.C. x 321().
() The term \dietary supplement" { (1) means a product (other than tobacco) intended to supplement the diet that bears
or contains one or more of the following dietary ingredients: (A) a vitamin; (B) a mineral; (C) an herb or other botanical; (D)
an amino acid; (E) a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or (F) a
concentrate, metabolite, constituent, extract, or combination of any ingredient described in clause (A), (B), (C), (D), or (E).
Id. Congress intended that this denition \encompass all those substances and materials that are presently contained in
dietary supplements as well as substance[s] derived from foods." S. Rep. No. 103-410, at 22 (1994). Under the expanded
denition, dietary supplements \include such substances as ginseng, garlic, sh oils, psyllium, enzymes, [and] glandulars."
Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, Dietary Supplement Health
and Education Act of 1994 (December 1, 1995) (visited Feb. 4, 2001) <http://vm.cfsan.fda.gov/dms/>.
18621 U.S.C. x 321()(2)(C).
187These forms may include powders, bars or drinks. S. Rep. No. 103-410, at 22 (1994).
18821 U.S.C. x 350(c)(1)(B)(i).
18921 U.S.C. x 321()(2)(B).
19021 U.S.C. x 321()(3). As dietary supplements are not considered to be foods for the purposes of the drug denition of
the FDCA, they do not receive the same safe harbor as foods. Specically, the provision that exempts \articles (other than
food) intended to aect the structure or any function of the body of man or other animals" from the denition of drug does
not apply to supplements. 21 U.S.C. x 321 (g)(1)(C).
29as biologics, or certied as antibiotics that were previously marketed as dietary supplements or food are
also considered to be dietary supplements unless the Secretary of Health and Human Services waives this
provision.191 The DSHEA further explicitly forbids the FDA from regulating dietary supplement ingredients
as food additives.192 The expanded denition of dietary supplements combined with the exemption of dietary
supplements from regulation as drugs or food additives represents a major victory for the supplement industry
and tremendously restricts the FDA's authority to regulate such products.
Dietary Supplement Label Exemption
In the DSHEA, Congress also relaxed standards regarding what constitutes the \labeling" of a dietary
supplement product.193 Prior to the passage of the DSHEA, literature \used in connection with the sale or
distribution of a product" was considered to be part of the supplement's labeling.194 Accordingly, the claims
and endorsements found in these pamphlets, articles, brochures, and other accompanying pieces of literature
19121 U.S.C. x 321()(3).
19221 U.S.C. x 321(s). An unfortunate result of this change is that dietary supplements are exempt from the Delaney Clause,
which protects consumers from carcinogenic substances. See 21 U.S.C. x 348(c)(3). \This is a potential health hazard as
many of the herbal supplements are plant-derived and exposed to cancer-causing pesticides. They are extracted and further
concentrated during the nal stages of production, thereby increasing the concentration of the carcinogen in the nal product."
Leticia M. Diaz, First St. John's Wort, Now SAM-e: Is Society as a Whole at Risk Without FDA Regulation of Psychiatric
Self-Medication, 9 Kansas J.L. & Pub. Pol'y 279 (Winter 1999).
193See 21 U.S.C. x 343-2.
194S. Rep. No. 103-410, at 23 (1994). For more than 50 years, the FDA had pursued this policy of associating books and other
publications to the foods and dietary supplements that they promoted. See I. Scott Bass & Anthony L. Young, Dietary
Supplement Health and Education Act: A Legislative History and Analysis 49 (1996). Courts often had to intervene in
the ongoing battle between the dietary supplement industry, health food stores (that often stocked both books and products),
and the FDA. See, e.g. Kordel v. United States, 335 U.S. 345 (1948) (nding that \labels" included associated materials, even
if physically separate from the product or package); United States v. Urbuteit, 335 U.S. 355 (1948) (holding that literature sent
\in a separate mail does not save the article from being misbranded"); United States v. Taller, 394 F.2d 435 (2d Cir.), cert.
Denied, 393 U.S. 839 (1968); United States v. ...Cove Vitamin and Pharm Inc., 204 F. Supp. 283 (E.D.N.Y. 1962); United
States v. 8 Cartons, More or Less, Molasses, etc. 97 F. Supp. 313 (W.D.N.Y. 1951); United States v. An Article of Drug
Consisting of 250 Jars, etc. of U.S. Fancy Pure Honey, etc., 218 F. Supp. 208 (E.D. Mich. 1963), a'd 344 F.2d 288 (6th Cir.
1965); United States v. \Sterling Vinegar and Honey", 338 F.2d 157 (2d Cir. 1964); United States v. General Nutrition, Inc.,
638 F. Supp. 556 (W.D.N.Y. 1986).
30were held to the same standards as information contained on a label attached to the product itself.195 As a
result, the FDA often seized either the literature itself or the products whose health benets the literature
promoted.196
The DSHEA eectively changed this law to exempt literature from the denition of \labeling" for dietary
supplement products provided that the materials meet certain criteria.197 Specically, retailers may now
make \third party" literature198 { including articles, book chapters, and scientic abstracts { available to
dietary supplement consumers if the literature if \reprinted in its entirety" and conforms to the following
provisions:
(1)
is not false or misleading;
(2)
does not promote a particular manufacturer or brand of a dietary supplement
(3)
is displayed or presented, or is displayed or presented with other such items on the same subject matter, so as to present a balanced view of the available scientic information on a dietary supplement;
(4)
if displayed in an establishment, is physically separate from the dietary supplements; and
195See S. Rep. No. 103-410, at 23 (1994).
196See, generally, I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative
History and Analysis 49-50 (1996).
197See 21 U.S.C. x 343-2(a).
198Although this section is commonly referred to as allowing \third party" literature, the language does not actually limit
who may author a publication. Accordingly, it appears that manufacturers and distributors of supplements can commission or
publish such literature themselves provided that it meets all of the statute's requirements, including nonpromotion of a specic
manufacturer or brand. See I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A
Legislative History and Analysis 51 (1996).
31(5)
does not have appended to it any information by sticker or any other method.199
These new labeling exceptions not only limited the FDA's ability to regulate the dissemination of health
claims and other information regarding supplements, but also explicitly placed the burden of proof on the
FDA \to establish that an article or other such matter is false or misleading."200
Nutritional Support, Structure/Function, and Health Claims
By explicitly authorizing the use of various types of statements and claims on dietary supplement labels,
the DSHEA broadened the scope of the exemption from the drug provisions of the FDCA, as set forth in
NLEA.201 As previously discussed, the NLEA created a type of safe harbor for food { and, by extension, for
supplements { by establishing a mechanism through which manufacturers could make label claims that char-
acterized the relationship of a given nutrient to a specic disease or health-related condition.202 These claims
would ordinarily be considered drug claims203 and thereby be subject to the arduous new drug application
requirements.204 The NLEA, however, provides such claims will not be considered to be drug claims if they
conform with a standard of \signicant scientic agreement" and are authorized in advance through FDA
regulation.205 The DSHEA leaves the NLEA health claims standard largely intact with respect to dietary
supplements, and merely establishes a Commission to study how to regulate label claims most eectively.206
20021 U.S.C. x 343-2(c).
201See 21 U.S.C. x 343(r)(1)(B).
202See 21 U.S.C. x 343(r)(1)(B).
203See 21 U.S.C. x 321(g).
204See 21 U.S.C. x 355.
205See 21 U.S.C. x 343(r)(3).
206See Dietary Supplement Health and Education Act of 1994, x 12. As will be discussed in greater depth later in this piece,
the Commission ultimately recommended that the same standards apply to both dietary supplements and conventional foods,
as detailed in the NLEA. See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims
and Freedom of Choice, 49 Fla. L. Rev. 663, 680 (1997).
32More importantly, however, the DHSEA further qualied the scope of the FDA's regulatory authority with
respect to dietary supplements by creating several new categories of allowable claims that require no pre-
market approval or preclearance by the FDA.207 In essence, the DSHEA allows manufacturers to make a
variety of statements that do not claim a direct correlation between a particular nutrient or ingredient and a
disease or health-related condition. Specically, manufacturers can now make claims about their supplement
products if
[t]he statement claims a benet related to a classical nutrient deciency disease and discloses
the prevalence of such disease in the United States, describes the role of a nutrient or
dietary ingredient intended to aect the structure or function in humans, characterizes the
documented mechanism by which a nutrient or dietary ingredient acts to maintain such
structure or function, or describes general well-being from consumption of a nutrient or
dietary ingredient.208
This provision expands a supplement manufacturer's power to make product claims in several key aspects.
First, this provision created a blanket safe harbor for any claims regarding nutrient deciency diseases.
Second, it establishes an armative right for supplement manufacturers to make claims regarding the eect
of a nutrient or dietary ingredient on the \structure/function" of the body or on a person's general well-
being. This right conrms the traditional notion that food labeled with structure/function claims is not
considered to be a drug. Although the DSHEA's new denition of dietary supplements clearly indicates that
supplements are not food for the purpose of the structure/function exemption from the drug denition of
the FDCA,209 this new labeling provision ensures that supplements may still make such claims. As a result,
the DSHEA explicitly authorizes structure/function and other claims for supplements due to their status
as supplements rather than allowing structure/function claims for supplements based upon their status as
food.210 By allowing supplement claims based on not only nutrients but also dietary ingredients211 with no
207See 21 U.S.C. x 343(r)(6).
209See Dietary Supplement Health and Education Act of 1994, x3(a).
210Conforming amendments to the DSHEA revised the denition of drug under the FDCA to reect such changes. See 21
U.S.C. x 321(g)(1).
211The Act does not explicitly dene \dietary ingredient."
33known nutritive value, the DSHEA creates an exemption from the drug denition that is arguably larger for
dietary supplements than it is for conventional foods.212
A manufacturer may make any such nutritional support or structure/function claim on the label of a dietary
supplement without FDA review.213 Such statements merely must be \truthful and not misleading"214 and
contain a disclaimer indicating that the statement has not been evaluated by the FDA and that the product
is not intended to \diagnose, treat, cure, or prevent any disease."215 These new labeling guidelines are
among the most important provisions of the DSHEA, as the safe harbors created for dietary supplements
allow manufacturers to make label claims that would previously have been either outright prohibited or
allowed only after some level of FDA review and approval.
Commission on Dietary Supplement Labels and Oce of Dietary Supplements
The DSHEA also established two groups to help study and provide recommendations on the regulation of
dietary supplements. The rst group, the Commission on Dietary Supplement Labels (the \Commission"),
was an independent, temporary body charged with the task studying label claims and the use of literature in
supplement sales to \evaluate how best to provide truthful, scientically valid, and not misleading information
to consumers."216 The Act directed that the seven members of this Commission were to be appointed by
the President and comprised of various unbiased scientic and nonscientic experts in the \manufacture,
regulation, distribution, and use" of supplement products.217 The Commission was allotted two years to
212One court suggested that a common-sense denition of food covered articles primarily used for \taste, aroma, or nutritive
value." Nutrilab, Inc. v. Schweiker, 713 F.2d 335, 338 (7th Cir. 1983).
213The manufacturer, however, must notify the FDA within \30 days after the rst marketing of the dietary supplement
...that such a statement is being made." 21 U.S.C. x 343(r)(6)(C).
21421 U.S.C. x 343(r)(6)(B).
21521 U.S.C. x 343(r)(6)(C).
216Dietary Supplement Health and Education Act of 1994, x 12.
217Dietary Supplement Health and Education Act of 1994, x 12.
34submit a nal report and recommendations regarding supplement regulation; subsequently, the FDA would
have 90 days to issue proposed regulations on the recommendations and two years to complete the rulemaking
process.218
The second group was a permanent Oce of Dietary Supplements (\Oce"), established within the National
Institutes of Health to explore the potential role of dietary supplements in healthcare improvement and \to
promote scientic study" of the health benets of supplements.219 Essentially, this Oce was intended
to be a clearinghouse for the results of scientic research regarding supplements and would advise other
governmental agencies, such as the FDA, on various supplement issues.220
Other Provisions
Several other important provisions of the DSHEA deserve a brief mention. One of the immediate eects of
the DSHEA was to once again upend the FDA regulatory scheme regarding dietary supplements. The Act
expressly declared the controversial June 18, 1993 ANPR to be \null and void and of no force or eect."221
The FDA was instead again directed to restudy the issue, with the assistance of the Commission on Supple-
ment Labels and the Oce of Dietary Supplements, and to issue a new set of regulations incorporating these
groups' recommendations and the changes embodied in DSHEA.222 Another set of provisions established
requirements for dietary supplement ingredient and nutrition information labeling.223
The DSHEA also addressed the issue of supplement safety in several ways. Taken as a whole, it is unclear
whether the safety provisions have an overall eect of improving or reducing the safety of supplement prod-
218Dietary Supplement Health and Education Act of 1994, x 12.
21942 U.S.C x 287c-1(b).
220See 42 U.S.C. x 287c-1(c). The Act specically directed the Oce of Dietary Supplements to provide advice regarding
dietary intake regulations, supplement safety, health-related and disease claims, and \scientic issues arising in connection with
the labeling and composition of dietary supplements." 42 U.S.C. x 287c-1(c)(3).
221Dietary Supplement Health and Education Act of 1994, x 11.
222See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat. 4325 (1994).
223See 21 U.S.C. x 343(s); 21 U.S.C. x 343(q)(5)(F).
35ucts. In some instances, the FDA appears to be given additional opportunities to closely regulate supplement
safety, and in other provisions the DSHEA seems to place additional burdens on the FDA. To illustrate,
one provision gives the FDA authority to set regulations prescribing good manufacturing practices for di-
etary supplements.224 The FDA is stripped of its power to regulate supplements under the food additive
provisions,225 but the Act also imposes new conditions under which supplements may be deemed to be
adulterated.226 One signicant result of these various provisions is that the burden of proof regarding safety
and eectiveness shifts from supplement manufacturers to the FDA.227
III.
1994-2001: THE IMPLEMENTATION AND IMPACT OF DSHEA
As is evident from the provisions described above, the DSHEA eectively strips the FDA of much of its
regulatory authority regarding dietary supplements. The practical impact of the limitations that the DSHEA
established upon the FDA has been \enormous,"228 and some commentators have even criticized the DSHEA
as \the greatest removal of FDA jurisdiction in the 90-some-year history of the FDA."229 Many of such
critiques reect the fact that the DSHEA blurred the boundary between drug claims that require premarket
224See 21 U.S.C. x 342.
225See 21 U.S.C. x 321(s).
226See, e.g., 21 U.S.C. x 342 (adding new dietary supplement-specic safety requirements to the adulterated food section of
the FDCA); 21 U.S.C. x 350(b) (establishing safety requirements for new dietary ingredients).
227See, e.g., 21 U.S.C. x 321(s); 21 U.S.C. x 342(f)(1)(B); 21 U.S.C. x 343-2(c).
228Michael Higgins, Hard to Swallow: While Federal Law Shut the Door on Regulation of Dietary Supplements, Marketing
Hype May be Leading the Popular Aids Up Courthouse Steps, 85 A.B.A. J. 60, 62 (June 1999).
229Michael Higgins, Hard to Swallow: While Federal Law Shut the Door on Regulation of Dietary Supplements, Marketing
Hype May be Leading the Popular Aids Up Courthouse Steps, 85 A.B.A. J. 60, 62 (June 1999) (quoting \James O'Reilly,
health law professor at the University of Cincinnati and a former chair of the ABA Administrative Law and Regulatory Practice
Section").
36approval and testing and food claims that are not subject to any such restrictions prior to being introduced
into the consumer market.230 Prior to the DSHEA, the FDA had fairly broad jurisdiction to evaluate and
restrict label claims that appeared to be making a drug claim, as dened in section 201 of the FDCA.231
The DSHEA, however, eviscerated the traditional notion of what constituted a drug claim by attempting
to categorize and distinguish among various types of label statements.232 Accordingly, after the enactment
of the DSHEA, fewer types of claims remained within the scope of the FDA's drug enforcement power, and
the FDA was faced with the challenge of publishing regulations that elaborated upon the subtle distinctions
established by Congress.
Specically, the DSHEA instructed the FDA to evaluate and enact rules regarding four categories of label
claims for dietary supplements. To help illustrate the framework that the DSHEA set in place, a description
of each of these types of claims is briey reviewed below. Each type of claim described below can be
conceptualized as a part of a continuum from claims that make extremely general promises of well-being or
nutritional support to claims that promise disease cure, treatment, or prevention.
The rst two types of claims may be considered together as statements of nutritional support. First, the
DSHEA allowed manufacturers to make statements that \claim[] a benet related to a classical nutrient
deciency disease" or describe \general well-being from consumption of a nutrient or dietary ingredient,"
provided that the manufacturer could substantiate that the statement was truthful and not misleading.233
Such claims do not require any sort of premarket approval by the FDA; manufacturers are merely required
to notify the FDA that the statement was being made within 30 days of rst marketing the product.234
230See Margaret Gilhooley, Herbal Remedies and Dietary Supplements: The Boundaries of Drug Claims and Freedom of
Choice, 49 Fla. L. Rev. 663, 666 (1997).
23121 U.S.C. x 321(g).
23221 U.S.C. x 343
23321 U.S.C. x 343(r)(6).
23421 U.S.C. x 343(r)(6)(C).
37These claims also require use of a disclaimer indicating that the FDA has not evaluated the statement.235
Second, the DSHEA authorized label claims that either describe \the role of a nutrient or dietary ingredient
intended to aect the structure of function in humans" or characterize \the documented mechanism by which
a nutrient or dietary ingredient acts to maintain such structure or function."236 As with the rst category
of claims, these \structure/function" claims do not require premarket review. Rather, manufacturers are
free to release products bearing such statements provided that they meet the aforementioned conditions of
notice, disclaimer, and truthfulness.237
The third and fourth categories of claims are those that establish a more direct causal relationship between a
particular nutrient or dietary ingredient and its alleged curative or preventative properties. Accordingly, the
third category of label statements is comprised of health claims, which are dened by the NLEA as a claim
that characterizes the relationship between a nutrient and a specic disease or health-related condition.238
Although such claims would ordinarily be considered to be drug claims, establishing the category of health
claims provides manufacturers with the opportunity to make such label statements without going through
the rigorous new drug approval process.239 Instead, the health claims category establishes the possibility
of a dierent procedural avenue to receive FDA premarket approval. Under this alternate system, dietary
supplements may bear disease or health-related statements if the FDA determines that the claim is supported
by \signicant scientic agreement" and issues a corresponding regulation.240 Finally, the fourth category,
drug claims, also applies to statements that bear a disease or health-related claim. Any such statement that
23521 U.S.C. x 343(r)(6)(C).
23621 U.S.C. x 343(r)(6)(A).
23721 U.S.C. x 343(r)(6).
23821 U.S.C. x 343(r)(1)(B).
239Some critics argue that the FDA's strict interpretation of the \signicant scientic agreement" standard for health claims
makes the standard for these claims as stringent as the standard used for approving new drugs. See infra
45-54.
24021 U.S.C. x 343(r)(3)(B). Any manufacturer may petition the FDA to evaluate a health claim; the NLEA gives the FDA
100 days to make a decision on the claim or to take further action. 21 U.S.C. x 343(r)(4)(A)(i). Once the FDA issues such a
regulation, any company, not just the one that originally petitioned the FDA, can use the claim on a product meeting criteria
outlined in the regulations. See United States General Accounting Office, Food Safety: Improvements Needed in
Overseeing the Safety of Dietary Supplements and \Functional Foods" 10 (July 2000).
38has not been authorized as a health claim is treated as a drug claim. Accordingly, drug claims must undergo
extensive premarket testing and review prior to use.241 The time and expense involved for processing a
new drug claim is much greater than for a health claim that does not require any independent study by the
manufacturer if it is supported by \signicant scientic agreement."
Issuing regulations to implement these categories in practical terms, however, was not to be an easy task.
In particular, the establishing the actual distinction between structure/function claims that do not require
premarket approval and health or drug claims that do require premarket approval proved to be one of the
most highly controversial aspects of the DSHEA, as this dividing line was clouded with great ambiguity.
Report of the Commission on Dietary Supplement Labels
The FDA, fortunately, did not have to attack this problem alone. The DSHEA had established a Commission
on Dietary Supplement Labels to help investigate label statements and to recommend to the FDA appro-
priate action for implementation.242 Yet this help was a long time in coming, as President Clinton \took a
year" after enactment of the DSHEA to appoint the seven members of the Commission.243 Subsequently,
the Commission researched the issues for two years and did not publish a nal report until November 1997,
more than three years after the President signed the DSHEA into law.244 The Commission's nal report
included, among other things, an analysis of health claims, structure/function claims, and the degree of
24121 U.S.C. x 355.
242Dietary Supplement Health and Education Act, x 12.
243William J. Skinner, R.Ph., J.D., Allowable Advertising Claims for Dietary Supplements, 5 J. Pharmacy & L. 309, 309
(1996). Commission members included Malden C. Nesheim, Ph.D., Professor of Nutrition and Provost Emeritus of Cornell
University; Annette Dickinson, Ph.D., Director of Scientic and Regulatory Aairs for the Council for Responsible Nutrition;
Norman R. Farnsworth, Ph.D., Research Professor of Pharmacognosy and Senior University Scholar of the College of Pharmacy
at the University of Illinois at Chicago; Margaret Gilhooley, L.L.B., professor at Seton Hall Univerisity School of Law; Shiriki
K. Kumanyika, Ph.D., M.P.H., Professor and Head of the Department of Human Nutrition and Dietetics at the University of
Illinois at Chicago; Robert S. McCaleb, President of the Herb Research Foundation; and Anthony Podesta, President of Podesta
Associates. See Commission on Dietary Supplement Labels, Membership of the Commission on Dietary Supplement
Labels (visited Mar. 26, 2001) <http://www.health.gov/dietsupp/member.htm>.
244See Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>. President Clinton signed the DSHEA on October 25, 1994.
39substantiation required for each.245
With respect to health claims, the Commission found that a high standard of evidence is appropriate, as
valid health claims may have tremendous public health benets and invalid health claims may encourage
behavior that is results in harmful and costly health consequences.246 The Commission also recognized that
diering standards for health claims on food and health claims on dietary supplements might lead to con-
sumer confusion and be bad public policy.247 Accordingly, the Commission recommended that the FDA use
the same process for health claim approval for supplements and for conventional foods. The report cautioned,
however, that although \signicant scientic evidence" is an appropriate standard to use in evaluating such
claims, the FDA should not interpret the standard so strictly \as to require unanimous or near-unanimous
support" and should obtain \broad input," such as from panels of scientists or other government agencies.248
Dissenting views within the Commission indicated that the interpretation of allowable structure/function
claims was a more contentious issue.249 Acknowledging that neither the DSHEA nor FDA regulations had
\specically outlined" allowable claims and the dierences between allowable structure/function claims and
unauthorized health or drug claims was dicult to distinguish, the Commission concluded that \the lack of
denition of the clear boundaries of these statements leaves many uncertainties."250 The Commission was
also divided with respect to several specic issues, including the following: whether claims may imply disease
prevention, how to regulate claims that indicate \an acute eect on the structure or function of a major
system," what the appropriate distinction was between allowable structure/function claims and drug claims
245See Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
246See Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
247See Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
248See Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>. The report suggested that the views of other government agencies be
given \serious consideration" and \considerable weight" in the FDA's analysis. See id.
249See Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
250Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
40referring to organs associated with major clinical conditions,251 and whether structure/function claims that
suggest an eect on a immune function or disease resistance are appropriate.252 Despite these dierences
in opinion, the Commission proposed some general guidelines for the FDA; however, they did not issue dis-
tinct recommendations.253 These guidelines do not appear to be too helpful, as they indicate that the FDA
will need to employ a case-by-case analysis and primarily seem to make generic comments that statements
should be useful, truthful, not misleading, and should not directly refer to or imply relationships to diseases
or health-related conditions.254
The Commission also considered what types of substantiation would be sucient for a nutritional support
claim. For statements involving the relationship of a nutrient to a classic nutrient deciency disease, the Com-
mission agreed that data should come from \recognized sources."255 Once again, structure/function claims
251Conditions include heart, liver, prostate, or circulatory problems. Commission on Dietary Supplement Labels, 1997
Report (visited Mar. 26, 2001) <http://www.health.gov/dietsupp/ch3.htm>.
252Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
253According to the report, guidelines are advice that agencies should consider as \they develop or implement activities related
to the availability of dietary supplements in the marketplace," whereas recommendations \call for consideration of changes in
existing regulations, development of new regulations, or legislative action." Commission on Dietary Supplement Labels,
1997 Report: Executive Summary (visited Mar. 27, 2001) <http://www.health.gov/dietsupp/execsum.htm>.
254Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>. In the FDA's case-by-case assessment of statements, the Commission sug-
gested the following seven guidelines:
1. Statements of nutritional support should provide useful information to consumers about the intended use of a product.
2. Statements of nutritional support should be supported by scientically valid evidence substantiating that the statements
are truthful and not misleading.
3. Statements indicating the role of a nutrient or dietary ingredient in aecting the structure or function of humans may be
made when the statements do not suggest disease prevention or treatment.
4. Statements that mention a body system, organ, or function aected by the supplement using terms such as stimulate,
maintain, support, regulate, or promote can be appropriate when the statements do not suggest disease prevention or treatment
or use for a serious health condition that is beyond the ability of the consumer to evaluate.
5. Statements should not be made that products restore normal or correct abnormal function when the abnormality
implies the presence of disease. An example might be a claim to restore normal blood pressure when the abnormality implies
hypertension.
6. Health claims are specically dened under NLEA as statements that characterize the relationship between a nutrient or
a food component and a specic disease or health-related condition. Statements of nutritional support should be distinct from
NLEA health claims in that they do not state or imply a link between a supplement and prevention of a specic disease or
health-related condition.
7. Statements of nutritional support are not to be drug claims. They should not refer to specic diseases, disorders, or
classes of diseases and should not use drug-related terms such as diagnose, treat, prevent, cure, or mitigate.
The guidelines also indicated that the FDA should provide manufacturers with letters of notication if a statement is deemed
to be an inappropriate structure/function claim. See id.
255Recognized sources would include \surveys that are components of the National Nutrition Monitoring and Related Research
Program, the publications derived from this program or publications in peer-reviewed journals." Commission on Dietary
Supplement Labels, 1997 Report (visited Mar. 26, 2001) <http://www.health.gov/dietsupp/ch3.htm>.
41proved to be more dicult to analyze and the Commission did not reach a clear recommendation. Rather,
the report merely acknowledges that substantiation can include various types of evidence256 developed either
by the manufacturer or another party, and that the level of substantiation required for a particular claim will
vary depending on the specic claim being made.257 For the purpose of practical application, such musings
are largely inconclusive.
Health Claims
In order to elucidate the diculties stemming from the ambiguous dierence between structure/function
claims and unauthorized health or drug claims fully, it is important to explore health claims as an alter-
nate avenue of allowing statements on supplements. Capturing the distinction between health and struc-
ture/function claims would have been much less critical to supplement manufacturers if the FDA was quick
or liberal in granting health claims. Instead, structure/function claims perhaps became more important
because the FDA was notoriously slow and reluctant to approve health claims, especially on dietary sup-
plements. As previously discussed, the FDA decided to apply the same standard to health claims made on
dietary supplement labels and on food labels.258 As the Commission's nal report supported this conclusion,
the FDA did not revise these rules in the aftermath of the DSHEA. Yet the FDA has only approved a fraction
of the claims it has considered and has labored over some of these decisions for years on end. Specically, the
FDA initially approved seven claims in 1993 and has authorized only seven more claims in the intervening
256The report suggests that substantiation evidence may include clinical studies, epidemiologic date, historical usage, animal
testing, and studies from peer-reviewed scientic journals. See Commission on Dietary Supplement Labels, 1997 Report
(visited Mar. 26, 2001) <http://www.health.gov/dietsupp/ch3.htm>.
257Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
258See Food Labeling; General Requirements for Health Claims for Dietary Supplements, 59 Fed. Reg. 395 (January 4, 1994),
codied at 21 CFR xx 20, 101.
42years.259 Only four of these fourteen total claims apply to dietary supplements,260 possibly due to the di-
culties in attributing a result to a specic nutrient, as discussed earlier in this piece. The FDA's treatment of
the claim regarding folic acid and neural tube defects is often cited as the quintessential example of how such
claims can labor through the regulatory system for tremendous lengths of time; the FDA did not authorize
this claim until 1996, four years after the CDC had originally recommended its adoption.261
Congress,262 the courts,263 and the public264 were disenchanted with the FDA's slow, restrictive procedure
to evaluate and approve health claims. Accordingly, in addition to the public pressure to approve more
health claims or at least to review health claims more promptly, the FDA faced challenges on two fronts, as
both Congress and the courts forced the FDA to modify its procedural regime regarding health claims.
259See Food and Drug Administration, Staking a Claim to Good Health: FDA and Science Stand Behind Health Claims
on Foods, FDA Consumer, Nov.-Dec. 1998 (visited Feb. 2, 2001) <http://vm.cfsan.fda.gov/dms/>. Subject to certain
requirements, the FDA has approved claims between calcium and osteoporosis; sodium and hypertension (high blood pressure);
dietary fat and cancer; dietary saturated fat and cholesterol and risk of coronary heart disease; ber-containing grain products,
fruits, and vegetables and cancer; fruits, vegetables, and grain products that contain ber, particularly soluble ber, and
risk of coronary heart disease, fruits and vegetables and cancer, folate (folic acid) and neural tube birth defects; dietary
sugar alcohol and dental caries (cavities); dietary soluble ber, such as that found in whole oats and psyllium seed husk,
and coronary heart disease; soy protein and coronary heart disease; plant sterol and plant stanol esters and coronary heart
disease; whole grain foods and coronary heart disease and certain cancers; potassium and blood pressure and stroke. See id.;
Office of Nutritional Products, Labeling and Dietary Supplements, Food and Drug Administration, Health Claim
Notification for Potassium Containing Foods, Oct. 31, 2000 (visited Mar. 27, 2001) <http://vm.cfsan.fda.gov/dms/>;
Office of Food Labeling, Food and Drug Administration, Health Claim Notication for Whole Grain Foods, July 1999
(visited Feb. 2, 2001) <http://vm.cfsan.fda.gov/dms/>. All of the authorized health claims to date relate a nutrient to a
reduced risk of disease; the FDA has not allowed any statements that claim to treat or mitigate disease. See United States
General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety of Dietary Supplements
and \Functional Foods" 3 n.2 (July 2000).
260Certain dietary supplements may include the health claims involving calcium, folic acid, dietary soluble ber, and plant
sterol. See Food and Drug Administration, Staking a Claim to Good Health: FDA and Science Stand Behind Health Claims
on Foods, FDA Consumer, Nov.-Dec. 1998 (visited Feb. 2, 2001) <http://vm.cfsan.fda.gov/dms/>. According to another
source, the four health claims that may be used by supplements are the ones regarding calcium, folic acid, dietary soluble ber in
the form of psyillium husk, and soy protein. See United States General Accounting Office, Food Safety: Improvements
Needed in Overseeing the Safety of Dietary Supplements and \Functional Foods" 18-19 (July 2000). The reasons for
these discrepancies are unknown.
261See Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Government
Regulation Five Years after Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food & Drug L.J.
567, 568 (1999). In 1992, the CDC recommended that neural tube defects at birth could be reduced by up to fty percent if
women of childbearing age received adequate folic acid. Despite this recommendation, the FDA banned the claim in 1993 and
only reversed its stance in 1996 after intense public pressure. See id.
262See Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296 (1997), codied at 21
U.S.C.
263See, e.g., Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999).
264See Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Government
Regulation Five Years after Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food & Drug L.J.
567, 568 (1999).
43In 1997, Congress passed sweeping legislation, the Food and Drug Administration Modernization Act
(\FDAMA"), designed to update the almost 60-year-old FDCA. Title III of the FDAMA included vari-
ous provisions designed to improve the regulation of food, including dietary supplements, and to ensure that
consumers are promptly informed of \scientically sound nutritional and health information," including the
\nutritional and health benets of food."265 To facilitate these goals, Congress amended section 403(r) of
the FDCA to provide for an expedited review of health claims. This amendment attempts to bypass the
FDA in many respects by allowing health claims based on authoritative statements. Under this new law,
claims that are not authorized by the FDA through a regulation may be made if
a scientic body of the United States Government with ocial responsibility for public health
protection or research directly relating to human nutrition (such as the National Institutes
of Health or the Centers for Disease Control and Prevention) or the National Academy of
Sciences or any of its subdivisions has published an authoritative statement,266 which is
currently in eect, about the relationship between a nutrient and a disease or health-related
condition to which the claim refers.267
A manufacturer hoping to take advantage of this provision must also comply with certain other requirements,
such as notice.268 The clause allows the FDA to retain some authority in this area, however, as it further
provides that such claims based on authoritative statements may only be made until the FDA issues a
regulation prohibiting or modifying the claim.269 Nevertheless, it seemed that the provisions in the FDAMA
could be interpreted to be essentially directing the FDA to recognize authoritative statements as sucient
to satisfy the \signicant scientic agreement" standard of the NLEA.
Although the FDAMA only referred to health claims on conventional foods, regulations proposed by the
26521 U.S.C. x 343(r)(7).
268120 days before the product is introduced into interstate commerce, the manufacturer must submit: (1) notice of the claim,
using the exact language that is to appear, and accurately representing the authoritative statement relied upon; (2) a copy of
the authoritative statement relied upon; and (3) \a balanced representation of the scientic literature" relating to the health
claim. 21 U.S.C. x 343(r)(3)(C).
26921 U.S.C. x 343(r)(3)(D)(i). A district court can also ascertain that the claim has not met all of the requirements and
prohibit its use. See 21 U.S.C x 343(r)(3)(D)(ii).
44FDA to implement the FDAMA provisions extended the use of authoritative statements as an alternative
to signicant scientic agreement to dietary supplements.270 Such an interpretation was consistent with
FDA policy since January 4, 1994 of applying the same health claims standard to dietary supplements and
food.271 Although Congress intended that the FDAMA streamline the health claims process and the FDA
has extended these provisions to dietary supplements, the practical eect of the authoritative statement
provision is unclear. The FDA is adopting the view that Congress intended the authoritative statement
\to serve as a presumptive surrogate for FDA's deliberative review of scientic evidence" and therefore
authoritative statements must also be based upon such a deliberative review of the evidence.272 The FDA is
also looking closely at whether the organization can be considered \authoritative" and whether the statement
can be attributed to the organization or is merely the product of certain employees.273 The FDA's eorts
with respect to authoritative statements may just be a thorough and precise application of the statutory
language contained in the FDAMA. Some commentators, however, have argued that the FDA's view is
unduly restrictive and is tantamount to obliterating all practical eect of the FDAMA and returning to
the former standard with respect to health claims.274 To date, the FDA has only approved two health
claims based on authoritative statements.275 The overall eect of the FDAMA on streamlining the health
270See Food Labeling: Use on Dietary Supplements of Health Claims Based on Authoritative Statements, 64 Fed. Reg. 3250
(proposed January 21, 1999).
271See Food Labeling; General Requirements for Health Claims for Dietary Supplements, 59 Fed. Reg. 395 (January 4, 1994).
272Food Labeling: Health Claims; Antioxidant Vitamins C and E and the Risk in Adults of Atherosclerosis, Coronary Heart
Disease, Certain Cancers, and Cataracts, 63 Fed. Reg. 34,084, 34,086 (June 22, 1998).
273Food Labeling: Health Claims; Antioxidant Vitamins C and E and the Risk in Adults of Atherosclerosis, Coronary Heart
Disease, Certain Cancers, and Cataracts, 63 Fed. Reg. 34,084 (June 22, 1998).
274See Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Government
Regulation Five Years after Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food & Drug L.J.
567, 574 (1999). Expressing concern that the FDA denied several health petitions, Representative Dan Burton, Chairman of
the House Committee on Government Reform and Oversight commented that FDA's interpretation of the FDAMA would \only
reinforce the existing censorship eected by the [signicant] scientic agreement standard." Id., quoting a letter from Rep. Dan
Burton to Michael Friedman, Lead Deputy Commissioner, Food and Drug Administration (Aug. 13, 1998).
275See Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Government
Regulation Five Years after Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food & Drug L.J. 567,
574 (1999); Food and Drug Administration, Staking a Claim to Good Health: FDA and Science Stand Behind Health Claims
on Foods, FDA Consumer, Nov.-Dec. 1998 (visited Feb. 2, 2001) <http://vm.cfsan.fda.gov/dms/>; Office of Nutritional
Products, Labeling and Dietary Supplements, Food and Drug Administration, Health Claim Notification for
Potassium Containing Foods, Oct. 31, 2000 (visited Mar. 27, 2001) <http://vm.cfsan.fda.gov/dms/>; Office of Food
Labeling, Food and Drug Administration, Health Claim Notication for Whole Grain Foods, July 1999 (visited Feb. 2,
45claims process and encouraging approval of more claims remains uncertain, as the evidence thus far has not
demonstrated a marked increase in the number of allowable health claims.
A recent court decision, Pearson v. Shalala,276 bites more deeply into the FDA's regulatory power over
health claims and forces a reevaluation not only of the signicant scientic agreement standard, but also
of the underlying concept of limiting the types of allowable label claims. In 1999, the D.C. Circuit Court
reversed the district court ruling and struck down FDA's approach to authorizing health claims under the
NLEA, nding that these regulation were too restrictive and violated manufacturers' First Amendment
freedoms.277
Pearson v. Shalala involved a challenge brought by marketers of dietary supplements, joined by two health
care advocacy organizations,278 against the rejection of four health claims that they had submitted to the
FDA. The FDA had rejected each of these four claims on the basis that they failed to meet the standard of
signicant scientic agreement established by the NLEA and further detailed by FDA regulations.279 Using
this test, the FDA found the scientic evidence to be inconclusive and refused to allow disclaimers in attempt
to cure the situation.280 In its evaluation, the court of appeals applied the three-part test used to evaluate
government regulation of commercial speech281 and found the FDA's restrictions to be impermissible, as there
was not a \reasonable" t between the restrictions and the agency's goals of advancing consumer health282
2001) <http://vm.cfsan.fda.gov/dms/>.
276Pearson v. Shalala, 164 F.3d 650 (D.C. Cir 1999).
277See Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999).
278The American Preventive Medical Association and Citizens for Health joined as appellants. Pearson v. Shalala, 164 F.3d
650 (D.C. Cir. 1999).
279See Pearson v. Shalala, 164 F.3d 650, 653-54 (D.C. Cir. 1999). The FDA adopted the signicant scientic agreement
standard via regulations promulgated at 21 C.F.R. x 101.14.
280See Pearson v. Shalala, 164 F.3d 650, 653-54 (D.C. Cir. 1999).
281The three factors used in the commercial speech doctrine, commonly referred to as the \Central Hudson test," include the
following considerations: (1) whether the government interest is substantial; (2) whether the regulation directly advances the
government interest asserted; and (3) whether there is a reasonable t between the government interest and the restriction. See
Central Hudson Gas & Elec. Corp. v. Public Serv. Comm'n, 447 U.S. 557 (1980).
282The court found that advancing consumer health through supplement regulation is at best a indirect eect and therefore
encounters diculty with the second prong of the Central Hudson test. See Pearson v. Shalala, 164 F.3d 650, 656 (D.C. Cir.
1999).
46and protecting against consumer fraud.283 Rather, the court found that the FDA's blanket refusal to consider
use of disclaimers for each of the health claims ran afoul of the principle that disclaimers are \constitutionally
preferable to outright suppression."284 Although acknowledging that the government should have more
leeway to suppress speech in order to prevent consumer confusion about a health product,285 the court
nonetheless rejected the government's argument that such use of disclaimers would confuse consumers \by a
multitude of claims with diering degrees of reliability."286 Accordingly, the court held that the FDA may
not reject potentially misleading health claims if a disclaimer could eliminate the potential deception; the
court conceded that if the evidence weighs against the health claim, the FDA \could deem it incurable by
a disclaimer and ban it outright."287 Appellants also challenged the FDA's use of the signicant scientic
agreement standard to screen health claims as being vague and lacking sucient denitional content or
guidance.288 Although the court of appeals did not reach this issue in its analysis, it nevertheless suggested
that the FDA might be violating the Administrative Procedure Act's prohibition on arbitrary and capricious
agency action.289 The court further indicated that the FDA is \entitled to proceed case by case, or, more
accurately, sub-regulation by subregulation [stet], but it must be possible for the regulated class to perceive
the principles which are guiding agency policy."290 Accordingly, it directed the FDA to explain this standard
on remand.291
283Pearson v. Shalala, 164 F.3d 650, 656-57 (D.C. Cir. 1999).
284Pearson v. Shalala, 164 F.3d 650, 657 (D.C. Cir. 1999). The court further explained that \when government chooses a
policy of suppression over disclosure { at least where there is no showing that disclosure would not suce to cure misleadingness
{ government disregards a `far less restrictive' means." Id., at 658.
285Pearson v. Shalala, 164 F.3d 650, 659 (D.C. Cir. 1999).
286Pearson v. Shalala, 164 F.3d 650, 659 (D.C. Cir 1999) (quoting Food Labeling; General Requirements for Health Claims
for Dietary Supplements, 59 Fed. Reg. 395, 405 (1994)).
287See Pearson v. Shalala, 164 F.3d 650, 659 (D.C. Cir 1999).
288See Pearson v. Shalala, 164 F.3d 650, 660 (D. C. Cir. 1999).
289See Pearson v. Shalala, 164 F.3d 650, 660 (D. C. Cir. 1999) (referencing 5 U.S.C. x 706(2)(A) (1994)).
290Pearson v. Shalala, 164 F.3d 650, 661 (D.C. Cir. 1999). The court stated that the \I know it when I see it" approach once
used by Justice Stewart with respect to obscenity is inappropriate for the FDA. Id., at 660 (quoting Jacobellis v. Ohio, 378
U.S. 184, 197 (1964).
291Pearson v. Shalala, 164 F.3d 650, 661 (D.C. Cir. 1999). On April 2, 1999, the U.S. Court of Appeals for the D.C. Circuit
denied the FDA's petition for a rehearing en banc. See Food Labeling: Health Claims and Label Statements for Dietary
Supplements; Strategy for Implementation of the Pearson Court Decision, 64 Fed. Reg. 67,289, 67,290 (December 1, 1999);
Pearson v. Shalala, 172 F.3d 72 (D.C. Cir. 1999). In a related matter, more than 18 months after the Pearson decision,
after conducting various information-gathering measures { such as soliciting scientic data and contracting with an outside
47Almost eleven months later, on December 1, 1999, the FDA published a notice outlining its strategy for
implementing the Pearson decision. This initial notice was vague and only provided a general overview
of the steps the FDA needed to take.292 In addition, the notice indicated that until the FDA completes
the rulemaking to reconsider its treatment of health claims for dietary supplements, it will deny without
prejudice all claims that do not meet the signicant scientic agreement standard.293 The FDA later revised
this interim enforcement strategy to allow an intermediate step between authorization and denial of a health
claim.294 For claims that do not meet the signicant scientic agreement standard but are supported by more
scientic evidence than weigh against the claim, the FDA \will consider exercising enforcement discretion"
organization to conduct a literature review regarding the health claims { the FDA ultimately refused to authorize the folic acid
claim even with clarifying disclaimers, nding the claim to be \inherently misleading." Pearson v. Shalala, 130, F. Supp. 2d
105, 110-11 (D.D.C. 2001). As a result, the dietary supplement manufacturers and sellers party to the original suit (\Pearson")
led another lawsuit in November 2000 in an attempt to enjoin the FDA's refusal of their health claim, arguing that the FDA's
actions have \fundamentally misread and misapplied the legal standard articulated by the Court of Appeals in Pearson." Id.
at 112.
In granting the preliminary injunction, the district court agreed that the FDA \appears to have at best, misunderstood, and
at worst, deliberately ignored, highly relevant portions of the Court of Appeals opinion." Id. at 112. The decision further
conrmed the Pearson holding that the agency must consider the use of disclaimers to cure only potentially misleading claims,
as such statements enjoy First Amendment protection, recognizing that such a standard places a \very heavy burden" on the
FDA if \it seeks to totally ban a particular health claim." Id. at 118-20. The court's remedy, however, was rather limited in
scope and was conned to a declaration that the FDA had acted unconstitutionally and in violation of the 1999 appellate court
decision in Pearson by refusing to authorize the claim. Id. at 120. Pearson was denied broader injunctive relief, as the court
again remanded to the FDA the task of drafting succinct and accurate disclaimers, noting that such a task was the role of the
agency, not of the courts. Id. at 120.
Although this decision reinforced the holding in Pearson and reconrmed the constitutional protections of supplement claims,
it is yet unclear what impact this recent development will have on the FDA's regulation and assessment of health claims.
After nding that the agency acted with \less than reasonable speed" by delaying its actions for 18 months after the appellate
court decision in Pearson, the district court noted that although it was not setting an absolute deadline for the formulation
of appropriate disclaimers by the FDA, it \anticipate[d]" that this task would be completed within 60 days. Id. at 120 n.34.
Almost three months later, it does not yet appear that the FDA has completed the review mandated by the district court.
Rather, the only perceivable agency response is a March 30, 2001 letter noting that its review is ongoing and hopefully will be
completed by April 20, 2001. See Letter Regarding Continuing Review of a Health Claim that Was the Subject of
the Pearson Court Decision, letter from Christine J. Lewis, Ph.D., Director, Oce of Nutritional Products, Labeling and
Dietary Supplements, Center for Food Safety and Applied Nutrition, FDA, to Jonathan W. Emord, Emord & Associates (Mar.
30, 2001) (available at <http://www.cfsan.fda.gov/dms/>).
292See Food Labeling: Health Claims and Label Statements for Dietary Supplements; Strategy for Implementation of the
Pearson Court Decision, 64 Fed. Reg. 67,289, 67,290 (Dec. 1, 1999). The strategy included reexamining the four claims at
issue in Pearson, issuing guidance on the \signicant scientic agreement standard," and holding public meetings regarding
other changes that needed to be made to the FDA's policies regarding health claims. See id.
293See Food Labeling: Health Claims and Label Statements for Dietary Supplements; Strategy for Implementation of the
Pearson Court Decision, 64 Fed. Reg. 67,289, 67,290 (Dec. 1, 1999).
294See Food Labeling; Health Claims and Label Statements for Dietary Supplements; Update to Strategy for Implementation
of Pearson Court Decision, 65 Fed. Reg. 59,855, 59, 856 (Oct. 6, 2000).
48and allowing \appropriate qualifying language" for the statement.295 In the interim, while the FDA debated
how best to regulate disclaimers on health statements, it published guidance for the industry regarding the
application of the signicant scientic agreement standard.296 Characterizing the standard as an objective
determination of whether qualied experts would support the substance/disease relationship of a health
claim with a high level of condence, this document detailed the process used by the FDA and the types of
data that the agency evaluates.297
It is yet unclear how this denitional guidance will aect the approval of health claims, if at all, as in theory
the FDA is merely articulating its present denition of signicant scientic agreement and is not developing
or employing a new standard. Mandating the consideration and use of disclaimers will likely have much
greater actual impact on the labels of commonly used supplement products. Although critics and supporters
of Pearson agree that the court's ruling will have signicant and sweeping implications, their speculations
regarding the scope and nature of such eects vary widely.298 Some commentators laud the court's decision
as one that \revives the notion" of consumer empowerment299 and \ensure[s] that FDA adopt suciently
exible policies that foster the broad dissemination of useful information to consumers."300 Others worry
that the ruling will hamstring FDA's powers to prevent deceptive conduct and fraudulent claims, noting that
the court failed to distinguish \among studies that are tentative, inconclusive, preliminary, non-replicable, or
295Food Labeling; Health Claims and Label Statements for Dietary Supplements; Update to Strategy for Implementation of
Pearson Court Decision, 65 Fed. Reg. 59, 855, 59, 856 (Oct 6, 2000).
296See Office of Special Nutritionals, Food and Drug Administration, Guidance for Industry: Signicant Scientic
Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplements, Dec. 22, 1999 (visited Mar. 28,
2001) <http://vm.cfsan.fda.gov/dms/>.
297See Office of Special Nutritionals, Food and Drug Administration, Guidance for Industry: Signicant Scientic
Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplements, Dec. 22, 1999 (visited Mar. 28,
2001) <http://vm.cfsan.fda.gov/dms/>.
298See, e.g., Michael H. Cohen, U.S. Dietary Supplement Regulation: Belief Systems and Legal Rules, 11 Hastings Women's
L.J. 3, 20 (2000); Steven B. Steinborn & Kyra A. Todd, The End of Paternalism: A New Approach to Food Labeling, 54 Food
& Drug L.J. 401, 411-12 (1999); David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson
v. Shalala, 54 Food & Drug L.J. 535, 552 (1999).
299Michael H. Cohen, U.S. Dietary Supplement Regulation: Belief Systems and Legal Rules, 11 Hastings Women's L.J. 3,
20 (2000).
300Steven B. Steinborn & Kyra A. Todd, The End of Paternalism: A New Approach to Food Labeling, 54 Food & Drug L.J.
401, 411-12 (1999).
49even out of step with mainstream science."301 Further, the generous acceptance of health claims arguably will
allow dietary supplements to be eectively marketed as drugs, removing many advantages of drug designation
and manufacturers' incentives to undergo the now superuous but still arduous new drug evaluation.302 Until
the FDA issues nal regulations on this issue and begins to apply its rules on a regular basis,303 the ultimate
eect of the Pearson decision on health claims and the likelihood of the above scenarios coming to fruition
remains uncertain. Similarly, it is too soon to ascertain the practical eect of the recent armation of the
Pearson opinion by the D.C. District Court304 and its corresponding reprimand to the agency for failing to
adequately consider or implement the Pearson holding and to act in a timely manner.
Structure/Function Claims
While manufacturers hoping to include health claims on their products had won a couple of victories with
the enactment of the authoritative statement provisions of the FDAMA and the ruling in Pearson v. Shalala,
health claims still faced intense premarket scrutiny by the FDA and the application of disclaimers to cure
misleading claims remained in a regulatory morass. The DSHEA, however, also provided manufacturers with
another path to making label claims without fear of sanction as a misbranded product. Structure/function
claims do not need premarket agency approval and could only be challenged if the FDA bore the burden
of proof to show that they were misleading or otherwise impermissible.305 Further, such claims arguably
require a lesser standard of proof for their claims, as the statute refers to \substantiation" rather than
301David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food & Drug
L.J. 535, 552 (1999).
302David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food & Drug
L.J. 535, 552 (1999).
303Frustrated with the FDA's inaction on this issue, dietary supplement manufacturers \complain[] the agency is dragging its
feet in establishing new regulations." Dierdre Davidson, Food Lobby Nibbles at FDA, Legal Times, May 8, 2000, at 15. In
addition, the food and beverage industry is lobbying the FDA to apply the decision in Pearson to food products as well as to
supplement products. See id.
304See supra note 291.
30521 U.S.C. x 343(r).
50\signicant scientic agreement" as the level of acceptable support.306 Most importantly, the DSHEA did
not provide clear guidance on the distinction between structure/function claims and disease claims. Absent
further regulation by the FDA, this created a potential loophole for manufacturers to make essentially disease
claims without complying with either the new drug application process or the more forgiving health claim
procedure.
As suggested by the DSHEA, the FDA skirted the controversial issue of where to draw the appropriate
line between structure/function and drug claims while it waited for guidance from the nal report of the
Commission.307 In the interim, the FDA began to promulgate proposed and nal regulations interpreting
and enacting other various provisions of the DSHEA.308 Although some of these regulations addressed the
mechanics of structure/function claims,309 none really tackled the heart of the issue. As previously discussed,
the Commission issued its draft report regarding labeling issues on June 24, 1997 and its nal report on
November 24, 1997.310 Subsequently, on April 28, 1998, the FDA proposed long-awaited regulations that
30621 U.S.C. x 343(r)(6)(B); 21 U.S.C. x 343(r)(3)(B).
307See Dietary Supplement Health and Education Act of 1994, x 12(e)(3).
308See, e.g., Food Labeling; Requirements for Nutrient Content Claims, Health Claims, and Statements of Nutritional Support
for Dietary Supplements, 60 Fed. Reg. 67,176 (proposed Dec. 28, 1995); Food labeling: Nutrient Content Claims: Denition
for \High Potency" Claim for Dietary Supplements and Denition of \Antioxidant" for Use in Nutrient Content Claims for
Dietary Supplements and Conventional Foods, 60 Fed. Reg. 67,184 (proposed Dec. 28, 1995); Food Labeling; Statement of
Identity, Nutrition Labeling and Ingredient Labeling of Dietary Supplements, 60 Fed. Reg. 67,194 (proposed Dec. 28, 1995);
Food Labeling; Requirements for Nutrient Content Claims, Health Claims, and Statements of Nutritional Support for Dietary
Supplements, 62 Fed. Reg. 49,859 (Sept. 23, 1997).
309For example, the FDA promulgated both a proposed and nal rule regarding the precise placement and appearance of the
disclaimer that must be contained in statements of nutritional support. See Food Labeling; Requirements for Nutrient Content
Claims, Health Claims, and Statements of Nutritional Support for Dietary Supplements, 60 Fed. Reg. 67,176 (proposed Dec.
28, 1995); Food Labeling; Requirements for Nutrient Content Claims, Health Claims, and Statements of Nutritional Support
for Dietary Supplements, 62 Fed. Reg. 49,859 (Sept. 23, 1997). Regulations further stated that a \dietary supplement could
bear a structure/function claim under the `(other than food)' exception to the drug denition in section 201(g)(1)(C) of the
[FDCA], provided that the claim was truthful, nonmisleading and derived from nutritive value." Statements Made for Dietary
Supplements Concerning the Eect of the Product on the Structure or Function of the Body; Availability of Citizen Petitions
for Comment, 65 Fed. Reg. 63,256, 63,256 (Oct. 23, 2000) (citing Food Labeling; Requirements for Nutrient Content Claims,
Health Claims, and Statements of Nutritional Support for Dietary Supplements, 62 Fed. Reg. 49,859, 49,860, 49,863, 49,864
(Sept. 23, 1997)). In addition, the FDA nalized the procedure by which manufacturers and other distributors of dietary
supplements must notify the agency of statements of nutritional support that appear on a product label. See Food Labeling;
Dietary Supplement; Nutritional Support Statement; Notication Procedure, 61 Fed. Reg. 50,771 (proposed Sept. 27, 1996);
Food Labeling; Notication Procedures for Statements on Dietary Supplements, 62 Fed. Reg. 49,883 (Sept. 23, 1997).
310See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body, 63 Fed. Reg. 23,624, 23,624 (proposed Apr. 29, 1998).
51dened the types of statements that could be used in structure/function claims.311
Relying heavily on the commentary and guidelines in the Commission's Final Report, the April 1998 proposed
regulations attempted to clarify the distinction between structure/function claims and disease claims.312 The
proposed regulations embraced the Commission's guidelines that structure/function claims should not imply
treatment or prevention of disease.313 Specically, the proposal indicated that statements that expressly or
implicitly \claim[] to diagnose, mitigate, treat, cure, or prevent disease" are considered to be disease claims
that would render the product a drug or would require it to have these claims preapproved through the health
claims process.314 To elaborate, the proposal lists criteria for determining whether a specic statement sat-
ises the above denition of disease claim and notes that \[a] statement that by itself would be considered
an acceptable structure/function claim could become a disease claim if, in context, an eect on disease were
expressed or implied."315 First, the proposal states that statements cannot expressly or implicitly316 claim
\an eect on a specic disease or condition."317 Second, claims may not indicate \an eect, using scientic
or lay terminology, on one or more signs or symptoms that are recognizable to health care professionals
or consumers as being characteristic of a specic disease or of a number of dierent specic diseases."318
Through this provision, the FDA attempts to establish a distinction between maintaining normal function
311See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body, 63 Fed. Reg. 23,624 (proposed Apr. 29, 1998).
312See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body, 63 Fed. Reg. 23,624, 23,625 (proposed Apr. 29, 1998).
313See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body, 63 Fed. Reg. 23,624, 23,625 (proposed Apr. 29, 1998).
314Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,632 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(1)).
315Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,626 (proposed Apr. 29, 1998).
316The remaining criteria detailed in this paragraph similarly are prohibited from both explicit and implied claims. See
Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,632 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(2)).
317Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,632 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(2)(i)).
318Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,632 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(2)(ii)).
52as an allowable structure/function claim and preventing or treating abnormal function as a disease claim.319
Third, structure/function statements may not claim \an eect on a consequence of a natural state that
presents a characteristic set of signs or symptoms recognizable to health care professionals or consumers as
constituting an abnormality of the body."320 The proposal denes \abnormalities" to include pregnancy,
aging, and premenstrual syndrome.321 Under the fourth criteria, the product may not claim an eect on a
disease through use of the product's name, use of the term \disease," use of \pictures, vignettes, symbols,
or other means," or citation to a publication title that refers to disease use.322 Manufacturers also cannot
associate structure/function claims with a particular class of products used for diseases, such as laxatives.323
Improper structure/function claims further include statements that a product substitutes or augments a par-
ticular disease therapy or \treats, prevents or mitigates" characteristic adverse signs or symptoms resulting
from disease treatment.324 Finally, two catch-all provisions indicate that structure/function claims may not
claim that the product helps the body respond to disease or \otherwise suggests an eect on a disease or
diseases."325
Although the above list of prohibited claim types already seems comprehensive, the FDA suggested in the
April 1998 proposed regulations that it intended to extend its power over nutritional support statements
still further. Specically, the agency proposed that a new denition of disease control consideration of struc-
ture/function and health claims. Arguing the current denition is too narrow and fails to include certain
319See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body, 63 Fed. Reg. 23,624, 23,632 (proposed Apr. 29, 1998).
320Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,632 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(2)(iii)).
321See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body, 63 Fed. Reg. 23,624, 23,627 (proposed Apr. 29, 1998).
322Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,632 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(2)(iv)).
323See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body, 63 Fed. Reg. 23,624, 23,627 (proposed Apr. 29, 1998)(to be codied at 21 C.F.R. x 101.93(g)(2)(v)).
324Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,627-28 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(2)(vi,vii,ix)).
325Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,627-28 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(2)(viii,x)).
53conditions, such as headaches, that are understood to be diseases, the FDA stated that a revised denition
is appropriate and would more accurately reect the medical understanding of disease.326 Under the current
denition at the time, disease \is damage to an organ, part, structure, or system of the body such that it
does not function properly (e.g., cardiovascular disease), or a state of health leading to such dysfunctioning
(e.g., hypertension); except that diseases resulting from essential nutrient deciencies (e.g., scurvy, pellagra)
are not included...."327 The new proposed denition broadened the scope of this provision considerably by
referring not specically to damage of the body but more generally to \any deviation from, impairment of,
or interruption of the normal structure or function of any part, organ, or system (or combination thereof) of
the body that is manifested by a characteristic set of one or more signs or symptoms (including laboratory
or clinical measurements that are characteristic of a disease), or a state of health leading to such deviation,
impairment, or interruption; except that diseases resulting from essential nutrient deciencies (e.g., scurvy,
pellagra) are not included...."328
The proposed regulations for structure/function claims set o a restorm of controversy, as the FDA was
ooded by more than 100,000 comments before the deadline of September 28, 1998. 329 Accordingly, the
FDA extended the comment period to August 4, 1999,330 ultimately receiving more than 235,000 comments
326See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body, 63 Fed. Reg. 23,624, 23,626 (proposed Apr. 29, 1998).
327Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,626 (proposed Apr. 29, 1998)(quoting 21 C.F.R. x 101.14(a)(6)). The denition of disease
is now found at 21 C.F.R. x 101.14(a)(5).
328Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,632 (proposed Apr. 29, 1998) (to be codied at 21 C.F.R. x 101.93(g)(1)).
329See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Public Meeting, 64 Fed. Reg. 36,824, 35,824 (July 8, 1999).
330See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Public Meeting, 64 Fed. Reg. 36,824, 36,824 (July 8, 1999).
54in response to the proposed rule,331 and scheduled a public meeting for August 4, 1999.332 Three issues
in particular generated the greatest controversy. First, critics decried the FDA's denitional revision as an
end-run attempt to circumvent legislative intent and to regain the control over dietary supplements that
Congress had deliberately removed through the NLEA, the DSA, the DSHEA, and the FDAMA.333 The
reliance on \normal function" or a normal body as a basis for the disease claim was further seen as awed,
as commentators observed that \[t]here is no such thing as a normal body" and \[v]irtually anything is a
deviation from a normal body."334 Accordingly, a literal reading of the new denition could theoretically
classify any claim as a drug or disease claim.335 Second, comments strongly objected to the classication
of natural states, such as aging, menopause, and pregnancy, as diseases.336 Finally, comment submitters
asserted that prohibiting implied disease claims contradicts congressional intent in the DSHEA.337
Through this process, the FDA received comments on every provision of the proposed regulations, including
ones that supported the rule, ones that indicated the restrictions were too harsh, and ones that stated that
the FDA had not gone far enough in its proposed structure/function regulations.338 Facing the virtually
impossible situation of satisfying all interested parties, complying with statutes and court decisions, and
upholding the mission of the FDA, the agency nally published a nal rule regarding dietary supplements on
331See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1000 (Jan. 6, 2000). Although the majority of the submissions were form
letters, more than 22,000 comments were individual letters. See id.
332See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Public Meeting, 64 Fed. Reg. 36,824, 36,824 (July 8, 1999).
333See, e.g., Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Govern-
ment Regulation Five Years after Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food & Drug
L.J. 567, 577-78 (1999); Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on
the Structure or Function of the Body; Public Meeting, 64 Fed. Reg. 36,824, 36,825 (July 8, 1999).
334Peter B. Hutt, Edited Transcript of Remarks of Peter Barton Hutt to NDMA Government Aairs Committee, Sept. 23,
1998, at 4-5 (cited in Laura A.W. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA, 54 Food &
Drug L.J. 623, 638 (1999)).
335See Laura A.W. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA, 54 Food & Drug L.J. 623,
638 (1999); Jenna Greene, Denition of Disease Sparks Furor, Legal Times, July 19, 1999, at 1.
336See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Public Meeting, 64 Fed. Reg. 36,824, 36,825 (July 8, 1999).
337See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Public Meeting, 64 Fed. Reg. 36,824, 36,825-26 (July 8, 1999).
338See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000 (Jan. 6, 2000).
55January 6, 2000.339 The bulk of the lengthy 50-page publication consisted of summarizing and responding
to comments, and the nal rule itself was for the most part identical to the regulation proposed in April
1998. Perhaps in response to the public outcry,340 however, the FDA relaxed its regulations in a few key
areas.
The modied provisions contained in the nal rule generally corresponded to the three most contested is-
sues. First, the FDA abandoned the new denition of disease that it had proposed and instead retained
the preexisting denition. According to the nal regulations, this action was in direct response to the large
number of comments that objected to the change in denition.341 Second, the FDA revised the proposed
rule 21 C.F.R. section 101.93(g)(2)(iii), which had characterized as disease natural states or conditions of
the body. The nal regulations qualify this rule to exclude from the denition of disease those \common
conditions associated with natural states or processes that do not cause signicant or permanent harm,"
such as normal pregnancy and hair loss due to aging.342 Finally, the FDA declined to revise its treatment
of implied health claims signicantly or to exclude all such implied claims from classication as drug claims.
In a small concession, however, the agency agreed that \the use in labeling of a publication title that refers
to a disease will be considered a disease claim only if, in context, it may be used to diagnose, treat, mitigate,
cure, or prevent disease," and modied this provision accordingly.343
In addition, the FDA reconsidered its stance on disclaimers and reversed the position it had taken in the nal
339Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body; Final Rule, 65 Fed. Reg. 1000 (Jan. 6, 2000).
340See Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Government
Regulation Five Years after Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food & Drug L.J.
567, 579 (1999).
341See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1000 (Jan. 6, 2000).
342See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1000 (Jan. 6, 2000) (codied at 21 C.F.R. x 101.93(g)(2)(iii)).
343See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1000 (Jan. 6, 2000) (codied at 21 C.F.R. x 101.93(g)(2)(iv)(C)).
56rule published on September 23, 1997.344 Rather, the January 2000 nal rule states that there is no longer
an exception from use of the required disclaimer for supplement claims that are \truthful, non-misleading,
and derived from nutritive value."345 The nal rule claried, however, that structure/function claims that
meet the same criteria do not require a disclaimer when used on conventional foods.346
The January 2000 nal rules did not, unfortunately, settle the issue of structure/function statements. Rather,
the process of rulemaking and guidance continues. In February 2001, more than six years after the enactment
of the DSHEA, the FDA published a notice requesting comments for guidelines in applying the January 2000
rules.347 To date, these guidelines have yet to be proposed. Further, the FDA has not addressed the issue
of what constitutes adequate substantiation of claims made under the structure/function rules. The FDA
has indicated that such rules or guidance will be forthcoming in the future.348
IV.
ASSESSMENT AND ANALYSIS OF THE CURRENT REGU-
LATORY SCHEME: A CRITIQUE OF THE DSHEA AND ITS
IMPLEMENTATION
Almost seven years after the enactment of the DSHEA, the FDA and the dietary supplement industry
344See Food Labeling; Requirements for Nutrient Content Claims, Health Claims, and Statements of Nutritional Support for
Dietary Supplements, 62 Fed. Reg. 49,859 (Sept. 23, 1997); supra note 309.
345Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body; Final Rule, 65 Fed. Reg. 1000, 1033 (Jan. 6, 2000).
346See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1033 (Jan. 6, 2000).
347Guidance on Applying the Structure/Function Rule; Request for Comments, 66 Fed. Reg. 11,172 (Feb. 22, 2001).
348See Guidance on Applying the Structure/Function Rule; Request for Comments, 66 Fed. Reg. 11,172 (Feb. 22, 2001).
57still have not reached a comfortable working equilibrium in the ongoing battle regarding supplement label-
ing. Some commentators suggest that the distinction between structure/function and health or drug claims
perhaps remains \the most controversial issue in the area of dietary supplement regulation today."349 In en-
acting the DSHEA, Congress intended to establish the legislative framework to enable consistent regulation
of supplements to guide industry compliance, and to empower consumers to make their own choices re-
garding supplement use through accurate, scientically-based label claims.350 The ensuing Act signicantly
undermined the FDA's power to regulate supplements and enabled increased consumer access to supple-
ments. Despite these limitations on its authority, the FDA, for the most part, has done an admirable job
in promulgating regulations that are faithful to the DSHEA and that attempt \to strike the right balance
between ensuring the safety and proper labeling of all these products while at the same time preserving
consumers' freedom of choice."351 The resulting rules strive to placate both sides of the debate, although
satisfying everyone involved is undoubtedly an impossible task. Although there are some notable gaps and
aws in the FDA's regulatory scheme, as will be addressed below, many of the problems with the current
regulatory scheme do not lie with the FDA's interpretation of the DSHEA. Rather, in fostering a system
that encouraged widespread access to and use of dietary supplements, Congress failed to provide the FDA
with an actionable scheme that would allow the agency to achieve its lofty legislative goals, comply with
constitutional limits, and fulll the mission of the FDA to protect the American public from fraudulent and
ineective products. Accordingly, the current regulatory system fosters consumer confusion and does not
provide clear guidance to the dietary supplement industry.
349Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Government
Regulation Five Years after Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food & Drug L.J.
567, 568 (1999).
350See Dietary Supplement Health and Education Act of 1994, x 2.
351S. Rep. No. 103-410, at 11 (1994) (citing statement of Dr. David Kessler, then Commissioner of the FDA to the Committee
on Labor and Human Resources (Oct. 21, 1993).
58Industry Guidance
The current regulatory scheme does not provide clear, actionable guidance to industry regarding what consti-
tutes an acceptable dietary supplement label claim. First, neither the DSHEA nor FDA regulations provide
a clear denition of a structure/function claim. Rather than armatively dening what an acceptable struc-
ture/function claim is,352 the regulations enacted in January 2000 focus upon dening a disease claim and
excluding such statements from use as structure/function claims. The FDA admits that under these rules
\it may be very dicult to draw clear lines between structure/function claims and disease claims," especially
on any principled basis.353 Yet the DSHEA did not provide any guidance to the agency regarding how to
establish this boundary. Although the DSHEA makes a linguistic dierentiation between claims that are
allowable without premarket approval by the FDA and claims that are considered drug claims, the lack of
legislative guidance on this area seems to make this distinction one that does not identify any true dierence.
Attempting to reconcile the various provisions as the DSHEA as consistently as possible and to identify a
distinction where there appears to be none,354 the FDA has left the industry with a series of confusing
rules. For example, the nal rule tries to distinguish between maintaining healthy function and treating
abnormal function, between health maintenance claims such as \maintains healthy cholesterol levels" and
implied disease claims such as \lower cholesterol,"355 and between \mild common conditions associated with
352See Arnold I. Friede, Dietary Supplements: Background for Dialogue Between the Industry and the Medical Profession, 53
Food & Drug L.J. 413, 417 (1998).
353Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body; Final Rule, 65 Fed. Reg. 1000, 1005 (Jan. 6, 2000). Despite this confusion, the agency asserts that \[t]he nal rule
creates uniform, enforceable requirements for structure/function claims. By doing so, the nal rule establishes a `level playing
eld for all members of the dietary supplement industry, and permits rational use of FDA's limited enforcement resources."'
See id., at 1008.
354The FDA notes that \[d]espite [this] dicult, implementing section 403(r)(6) of the act requires the agency to draw these
lines. FDA would not be carrying out its statutory obligations if it abdicated responsibility for distinguishing between the
two types of claims, and instead permitted dietary supplements to disseminate information about specic disease states."
Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body; Final Rule, 65 Fed. Reg. 1000, 1005 (Jan. 6, 2000).
355Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
59natural states" and serious conditions associated with a stage of life or normal physiological process.356
Interpretation of these regulations often depends on the circumstances of use357 or the context in which the
claim is presented.358 Comments to the January 2000 rule indicate that the supplement industry is not sure
how to apply these regulations in practice;359 the agency has also recognized that the industry needs further
guidance.360
Second, the lack of guidance regarding adequate or appropriate substantiation of structure/function claims
is a major regulatory hole. The DSHEA provides that manufacturers must have \substantiation that [state-
ments of nutritional support] are truthful and not misleading," but does not dene \substantiation."361
In 1997, the Commission's Final Report documented that the industry had been asking for guidance on
\what constitutes appropriate documentation for a statement of nutritional support" from a \responsible
vendor."362 Accordingly, the Report provided guidance to the FDA regarding what types of substantiation
might be adequate to support a nutritional support claim.363 In addition, several comments regarding the
April 1998 proposed structure/function rule requested FDA guidance on claim substantiation, noting that
\adequate substantiation is critical to ensuring that consumers receive truthful and accurate information
about the benets of dietary supplements."364 Nevertheless, the FDA expressly declined to address this
of the Body; Final Rule, 65 Fed. Reg. 1000, 1018 (Jan. 6, 2000).
356Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body; Final Rule, 65 Fed. Reg. 1000, 1020 (Jan. 6, 2000).
357See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1006 (Jan. 6, 2000).
358See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1011 (Jan. 6, 2000).
359See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000 (Jan. 6, 2000).
360See Guidance on Applying the Structure/Function Rule; Request for Comments, 66 Fed. Reg. 11,172 (Feb. 22, 2001).
36121 U.S.C. x 403(r)(6).
362Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
363Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
364See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure
or Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1031-32 (Jan. 6, 2000); United States General Accounting
Office, Food Safety: Improvements Needed in Overseeing the Safety of Dietary Supplements and \Functional
Foods" 5 (July 2000) (\[B]oth food and dietary supplement industry associations have said they believe it is important for
FDA to take enforcement actions against unsupported claims."). One of the submitted comments originated with the Bureau
60issue when promulgating its nal structure/function rule. Instead, the FDA indicated that it \may provide
additional guidance" regarding substantiation at a future date, suggesting for the time being that manu-
facturers look to the Commission report for guidance.365 Unfortunately, the Commission report does not
detail the circumstances in which the dierent types of substantiation it suggests may be appropriate, and
members of the Commission disagreed on some critical points, such as whether historical use would alone be
sucient to substantiate a claim or whether scientic support is needed for all health statements.366 More
than a year after publishing the January 2000 nal rule, the FDA issued another notice that acknowledged
the agency had yet to address the question of substantiation, but gave no indication of when such guid-
ance would be forthcoming.367 Absent such guidance, even the most carefully delineated rules regarding
appropriate structure/function claims lose much of their bite. Members of the dietary supplement industry
cannot know which nutritional support statements, even if in compliance with the denitional limitations
of the structure/function rule, are authorized under the DSHEA and safe from FDA enforcement action, as
the statements may be found to have insucient scientic support. 368 Further, a lack of substantiation
guidance will likely increase the costs of industry compliance with FDA regulations. Without guidance on
the substantiation standard, this issue is roughly analogous to the one addressed by the court in Pearson,
which decried \arbitrary and capricious" agency action and noted that \it must be possible for the regulated
of Consumer Protection of the Federal Trade Commission. This comment recommended that \any nal rule reiterate explicitly
the requirement that structure/function claims be adequately substantiated" and that \FDA include guidance in the nal rule
as to what constitutes adequate substantiation of a structure/function claim." Bureau of Consumer Protection, Federal
Trade Commission, Comments Regarding Regulations on Statements Made for Dietary Supplements Concerning
the Effect of the Product on the Structure or Function of the Body; Proposed Rule (Aug. 27, 1998) (visited Mar.
31, 2001) <http://www.ftc.gov/be/v980023.htm>.
365See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1031-32 (Jan. 6, 2000).
366Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
367See Guidance on Applying the Structure/Function Rule; Request for Comments, 66 Fed. Reg. 11,172, 11,172 (Feb. 22,
2001).
368The Commission on Dietary Supplement Labeling notes that \[f]ollowing appropriate guidelines for substantiation could
allow manufacturers to have more condence that a statement will be sustained if challenged by regulatory agencies." See Com-
mission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001) <http://www.health.gov/dietsupp/ch3.htm>.
61class to perceive the principles which are guiding agency action."369 Under the current system, the industry
is still left guessing as to which statements will not be deemed misbranding.
Further confusing the issue, manufacturers cannot look to anecdotal evidence of acceptable or unacceptable
label claims for guidance, as resource constraints have generally precluded the FDA from enforcing the struc-
ture/function notice rules and ensuring the accuracy of label statements.370 The FDA estimated that as
of April 1998, approximately 22,500 dietary supplement labels included structure/function claims, yet the
agency had received only 2,300 claim notications.371 By January 6, 2000, the agency had received a total
of 5,200 claim notices and had objected to 336 of these claims.372 None of these objections, however, raised
the issue of claim substantiation; the FDA has never requested such information from dietary supplement
manufacturers nor initiated enforcement action to investigate questionable claims.373 Manufacturers there-
fore cannot look to enforcement proceedings to benchmark their own actions. Absent a clear denition of
a structure function claim, guidance regarding adequate claim substantiation, or consistent enforcement of
applicable rules, manufacturers have little concrete guidance to rely on and regulation remains largely ad
hoc.
369Pearson v. Shalala, 164 F.3d 650, 660-61 (D.C. Cir. 1999).
370See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 5 (July 2000) (\According to an FDA ocial, the agency has chosen
to use its limited resources on regulating product safety rather than on taking enforcement actions against problematic label
claims.").
371See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1004 (Jan. 6, 2000). The DSHEA requires that a manufacturer making
a nutritional support claim notify the FDA of the claim within 30 days of rst marketing the supplement. See 21 U.S.C. x
343(r)(6)(C). In citing these statistics, the agency conceded that some notications contain multiple claims, but noted that
\they do not average 10 claims per notication," indicating that many manufacturers were failing to comply with the notice
requirement. Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure
or Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1004 (Jan. 6, 2000).
372See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 21 (July 2000).
373See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 5, 18, 21 (July 2000).
62Consumer Confusion
The eects on consumers of the DSHEA and subsequent FDA regulation are arguably more important
than the lack of industry guidance. Consumer implications are especially critical as the dietary supplement
market has continued to grow rapidly since the enactment of the DSHEA. In 1994, an estimated 50 percent
of Americans regularly consumed supplements.374 By 1997, this gure had grown to an estimated 70 percent
of households,375 and is likely higher today. Correspondingly, consumer sales of dietary supplements totaled
at least $4 billion in 1994376 and reached $14.7 billion in 1999. As consumer reliance on dietary supplements
has appeared to increase at the same time that legislative changes relaxed the standards for supplement
manufacturers, allowing more products and more health and nutritional support claims on the market, this
has compounded the possibilities of consumer confusion over supplement products.
Regulatory Framework
The current regulatory process is awed, as it fails to ensure that consumers receive accurate information
based on scientic studies of the health and nutrition benets related to supplement use. Rather than
empowering consumers to make positive and informed health choices regarding dietary supplements, the
current method of disseminating supplement information often leads to consumer confusion and perhaps
even consumer fraud.
374Dietary Supplement Health and Education Act of 1994, x 2.
375According to 1997 survey conducted by the Hartman and New Hope research group, \approximately 70 percent of all
households reported using vitamins, minerals, or herbal supplements in the past 6 months. Regulations on Statements Made
for Dietary Supplements Concerning the Eect of the Product on the Structure or Function of the Body; Final Rule, 65 Fed.
Reg. 1000, 1045 (Jan. 6, 2000).
376Dietary Supplement Health and Education Act of 1994, x2. In a slightly dierent analysis, the General Accounting Oce
reported $9.8 billion in sales in 1995. Although it is conceivable that the market grew rapidly, it is probably unrealistic that
it more than doubled in size in one year. Rather, a slightly dierent estimation of sales or attribution of what is considered a
dietary supplement likely accounts for a portion of this variance.
63First, the lack of substantiation guidelines and the FDA's failure to enforce notice rules or to investigate
questionable claims, as discussed above, have signicant implications for consumers as well as the industry.
The patchwork, ad-hoc regulatory approach currently in place does little to assist consumers in making
informed choices, as there is no guarantee that such claims are truthful, nonmisleading, or meet any level
of scientic agreement. At the worst, such claims may be false, misleading, or inaccurate. At best, this
system results in the proliferation of a number of claims supported by vastly dierent amounts of evidence;
for example, consumers have no way to distinguish those structure/function claims based solely on historical
use from those supported by a signicant body of scientic evidence.377 In this regulatory mayhem, manu-
facturers who are unethical or loosely interpret the denition of \substantiation" do not fear that the FDA
will either catch or bring enforcement actions against their questionable claims; the system provides little or
no incentive for them to study products more thoroughly and to ensure that claims are scientically-based
and accurate, as Congress intended in the DSHEA.378 Unwitting consumers either are unaware that claims
are of varying levels of quality or are forced to bear the burden of self-evaluation of claims, a technical task
that few consumers can do themselves.379 As noted by the Commission in its Final Report, \[establishing
guidelines that manufacturers could follow] would increase the likelihood that statements are will be appro-
priately supported and would provide consumers with some basis for judging the soundness of the statements
that are made."380
The decision in Pearson v. Shalala further erodes assurances that any claims have met a specied scientic
standard, as now consumers may not be able to rely on even health claims as having passed \signicant
377See, e.g.,Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary Supplements: Examining Govern-
ment Regulation Five Years after Enactment of the Dietary Supplement Health and Education Act of 1994, 54 Food & Drug
L.J. 567, 568 (1999) (\Inexpensive products marketed by marginal companies with no manufacturing standards and minimal
scientic support appear on the same shelves as products of more reputable companies that meet strict quality standards and
have been subjected to extensive scientic study.").
378Dietary Supplement Health and Education Act of 1994, x 2. In brief, the process has no \bite."
379See Federal Trade Commission, Dietary Supplements: An Advertising Guide for Industry (visited Mar. 31, 2001)
<http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
380See Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch3.htm>.
64scientic scrutiny." Theoretically, this ruling suggests that manufacturers can make health claims that
are \tentative, inconclusive, preliminary, non-replicable, or even out of step with mainstream science,"381
provided that the claim also includes a specically-worded disclaimer. Under such a system, consumer con-
fusion would escalate, as manufacturers could frequently change the wording of disclaimers to reect new
studies. Market research academics have indicated that consumers understand short label messages better
than complicated legal disclaimers on packages,382 and it is unlikely that \consumers would be reread-
ing labels of familiar products for updated information."383 Under this system, it is possible that neither
structure/function claims nor health claims with an appropriate disclaimer will be held to a consistent or
scientically-based standard.
Second, inconsistent standards used by agencies with jurisdiction over the marketing and labeling of sup-
plements fosters consumer confusion. Under a long-standing agreement, the FDA and the Federal Trade
Commission (\FTC") share joint responsibility for the marketing of dietary supplement products.384 The
FDA's authority extends to supplement labeling, package inserts, and other point-of sale promotional ma-
terials.385 The FTC maintains primary jurisdiction over the advertising of dietary supplement products,
including print and broadcast advertisements, infomercials, Internet advertisements catalogs, and other di-
rect marketing materials.386 In a guide compiled specically for the dietary supplement industry, the FTC
outlined its general approach to truthful advertising as being comprised of the following two issues: \1)
381David C. Vladeck, Devaluing Truth: Unveried Health Claims in the Aftermath of Pearson v. Shalala, 54 Food & Drug
L.J. 535, 552 (1999).
382Statement of Bruce Chassy, University of Illinois (cited in Phil Wallace, FDA's Quandary Over How to Regulate Health
Claims After Pearson Reected at Meeting, 42 Food Chemical News, Apr. 10, 2000, at 14).
383Statement of Alice Lichtenstein, Tufts University (cited in Phil Wallace, FDA's Quandary Over How to Regulate Health
Claims After Pearson Reected at Meeting, 42 Food Chemical News, Apr. 10, 2000, at 14).
384See Bureau of Consumer Protection, Federal Trade Commission, Comments Regarding Regulations on State-
ments Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the
Body; Proposed Rule (Aug. 27, 1998) (visited Mar. 31, 2001) <http://www.ftc.gov/be/v980023.htm> (referencing FTC-FDA
Liaison Agreement, 4 Trade Reg., Rep. (CCH)
{ 9851 (1971)).
385See Federal Trade Commission, Dietary Supplements: An Advertising Guide for Industry (visited Mar. 31, 2001)
<http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
386See Federal Trade Commission, Dietary Supplements: An Advertising Guide for Industry (visited Mar. 31, 2001)
<http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
65advertising must be truthful and not misleading; and 2) before disseminating an ad, advertisers must have
adequate substantiation for all objective product claims."387 Supplement advertising is primarily addressed
through three sections of the FTC Act. Section 5 of the FTC Act prohibits \deceptive advertising" and other
\deceptive or unfair acts or practices;" sections 12 and 15 forbid \advertisements that are misleading in a
material respect" for a variety of products, including food and supplements.388 The FTC typically requires
that supplement claims in advertising be substantiated by \competent and reliable scientic evidence."389
Problems for consumers arise as the \competent and reliable scientic evidence" seems less stringent than
the \signicant scientic agreement" standard the FDA requires for health claims. It is unclear how the FTC
standard compares to yet-undened \substantiation" requirement for structure/function claims, although it
appears that the FTC's standard here may also be more relaxed than the requirements the FDA may im-
pose.390 It is clear, however, that although the FTC will generally defer to the FDA's assessment of whether
a specic health claim has adequate substantiation, \there may be certain limited instances when a carefully
qualied health claim in advertising may be permissible under FTC law, in circumstances where it has not
been authorized for labeling."391 In other words, consumers may be barraged with supplement claims in
387Federal Trade Commission, Dietary Supplements: An Advertising Guide for Industry (visited Mar. 31, 2001)
<http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
388Bureau of Consumer Protection, Federal Trade Commission, Comments Regarding Regulations on Statements
Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body;
Proposed Rule (Aug. 27, 1998) (visited Mar. 31, 2001) <http://www.ftc.gov/be/v980023.htm>
389See Federal Trade Commission, Dietary Supplements: An Advertising Guide for Industry (visited Mar. 31, 2001)
<http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
390For example, the FDA historically has been criticized for being overly cautious and restrictive in its evaluation of supplement
claims. Although, as previously discussed, structure/function claims have yet to be subjected to this type of intense scrutiny, it
is conceivable that FDA guidance will require rigorous support for these claims as well. Further, the FDA suggests in its January
2000 nal rule regarding structure/function claims that it agrees with much of the guidance of the Commission and that the sup-
plement industry might consider following these guidelines as a proxy for FDA regulation for the present time. See Regulations
on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function of the Body; Fi-
nal Rule, 65 Fed. Reg. 1000, 1031 (Jan. 6, 2000). One of the issues discussed by the Commission was whether historical use alone
would be sucient to substantiate a statement of nutritional support; Commission members were divided on this issue. See Com-
mission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001) <http://www.health.gov/dietsupp/ch3.htm>.
The FTC's guide for the dietary supplement industry suggests, however, that claims based solely on historical use may be
allowed if consumers understand this purpose. See Federal Trade Commission, Dietary Supplements: An Advertising
Guide for Industry (visited Mar. 31, 2001) <http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
391See Federal Trade Commission, Dietary Supplements: An Advertising Guide for Industry (visited Mar. 31, 2001)
<http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm>.
66advertising that the product labels cannot bear themselves. It is likely that consumers either will not read
to the supplement label and realize the inconsistency or will not understand what the inconsistency means.
Further, as the FTC has limited enforcement resources, outrageous advertising statements and marketing
hype easily slide by.392 Finally, the provisions in the DSHEA that exempt point-of-sale publications from
labeling status potentially exacerbate this inconsistency, as such publications are essentially removed from
the scope of the FDA's jurisdiction, are constrained by relatively few restrictions, and may contain claims
not authorized on supplement labels.393 In a climate where \[e]vidence suggests that the American public
obtains more information about diet and health from the media than from physicians and dietitians," using
more relaxed standards for claims via these forms of expression may not signicantly further the cause of
consumer protection.394
Blurring of Boundaries
The DSHEA and subsequent regulations, legislative action, and court decisions have blurred the lines be-
tween food, drugs, and dietary supplements. The elimination of sharp demarcations has resulted in a system
392See Michael Higgins, Hard to Swallow: While Federal Law Shut the Door on Regulation of Dietary Supplements, Marketing
Hype May be Leading the Popular Aids up Courthouse Steps, 85 A.B.A. J. 60, 60 (June 1999). For example, marketers have
hyped a supplement with supposed aphrodisiacal qualities as \Excellent Viagra Alternative! Increase Sex Drive! Build Muscle
Faster! Feel Younger!" and another supplement with alleged antiviral eects as being \designed for patients suering from
rheumatoid arthritis" or \designed for patients suering from frequent herpes syndrome." Id. at 62. The FDA would clearly
classify such claims as disease claims. See Regulations on Statements Made for Dietary Supplements Concerning the Eect
of the Product on the Structure or Function of the Body, 63 Fed. Reg. 23,624 (proposed Apr. 29, 1998); Regulations on
Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function of the Body;
Final Rule, 65 Fed. Reg. 1000 (Jan. 6, 2000). Dietary supplement executives note, however, that taking risks and pung up
claims used in advertising is an industry trend. Unauthorized advertising on the Internet may be especially dicult for the
FTC to regulate, given the scope of the medium. In 1998, the FTC coordinated a \surf day" with various consumer groups to
attempt to locate Web sites on which members of the dietary supplement industry made prohibited claims about their products.
Although 1,200 sites were identied through this eort, a FTC attorney noted that a FTC crackdown on such ads is unlikely
given the volume of violations. Michael Higgins, Hard to Swallow: While Federal Law Shut the Door on Regulation of Dietary
Supplements, Marketing Hype May be Leading the Popular Aids up Courthouse Steps, 85 A.B.A. J. 60, 60 (June 1999) (citing
statements of Michelle Rusk, an attorney at the FTC's Division of Advertising Practices).
393See 21 U.S.C. x 343-2; Michael H. Cohen, U.S. Dietary Supplement Regulation: Belief Systems and Legal Rules, 11
Hastings Women's L.J. 3, 12 (2000).
394See Commission on Dietary Supplement Labels, 1997 Report (visited Mar. 26, 2001)
<http://www.health.gov/dietsupp/ch4.htm>.
67that erodes the ability of consumers to make informed health choices yet simultaneously overwhelms them
with a barrage of new information and products. Rather than fullling the stated goals of the DSHEA,395
the prevailing atmosphere of ambiguity is responsible for consumer confusion, claim puery by manufactur-
ers, an increasing reliance on dietary supplements as a replacement for traditional medical treatment, and
inconsistent treatment of claims on food and dietary supplements.
In a regulatory scheme where the dietary supplement industry { which has a signicant nancial stake in
reviewing, commenting upon, understanding, and properly implementing regulations regarding label claims
{ remains confused about the distinctions between health claims and structure/function claims and the
FDA itself notes that such distinctions are elusive and dicult to dene, it is of little wonder that prelimi-
nary FDA research indicates that consumers also do not understand the intended dierences between these
types of claims.396 Although the FDA has noted that its attempts to clarify the distinction between struc-
ture/function and disease claims are intended to help \consumers make more informed and wiser choices,"397
it does not appear that the agency successfully reached these policy goals. Rather, comments submitted to
the FDA document that consumers incorrectly view both structure/function and health claims as \disease
treatment or prevention claims."398 Accordingly, consumers may misinterpret structure/function claims as
indicating that a product can help prevent, treat, or cure a disease rather than understanding them for their
more qualied purpose of merely describing how a product aects the body's structure, function, or general
well-being.399
395See Dietary Supplement Health and Education Act of 1994, x 2.
396See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 23 (July 2000).
397Statement of William Shultz, Deputy Commissioner for Policy, FDA (quoted in Michele Simon, Still Cloudy, With Little
Chance of Clearing: FDA's Proposed Rule on Structure/Function Claims for Dietary Supplements, 11 Hastings Women's
L.J. 23, 23 (2000)).
398United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety of
Dietary Supplements and \Functional Foods" 23 (July 2000).
399See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 5, 18, 23 (July 2000).
68The use of the statutorily-required disclaimer400 or of carefully constructed language restraints in claims will
likely be insucient to cure this problem of claim misinterpretation. As previously noted, the lay consumer
is unlikely to notice or to attach great signicance to the required disclaimer on structure/function claims.
One commentator further hypothesized that the \alluring promises" made in these claims contribute to
this cavalier dismissal of disclaimers.401 If consumers truly discounted the accuracy of structure/function
claims based on label disclaimers, it seems unlikely that consumers would support the supplement lobby
as strongly or that the dietary supplement market would be realizing such rapid growth.402 The linguistic
manipulations required by the nal January 2000 structure/function rule may only exacerbate consumer
confusion. Carefully worded claims such as \helps maintain intestinal ora"403 or \cleanses the blood"404
will likely bae, rather than illuminate, the average consumer. Similarly, consumers will probably fail to
understand the distinction between \supports the immune system" as an allowable structure/function claim
and \supports the body's ability to resist infection" as a prohibited disease claim.405
The natural tendencies of merchants to attempt to improve sales by bolstering the public perception of
their products' qualities, within legal limits, further confounds the issue of consumer confusion. With the
diculties inherent in successfully gaining premarket approval of a health claim, stretching the seemingly
ambiguous and malleable boundaries of structure/function claims likely appears as an particularly attrac-
400See 21 U.S.C. x 343(r)(6)(C).
401Leticia M. Diaz, First St. John's Wort, Now SAM-e: Is Society as a Whole at Risk Without FDA Regulation of Psychiatric
Self-Medication, 9 Kansas J.L. & Pub. Pol'y 279 (Winter 1999).
402The growth of supplements cannot be solely attributed to perceived health benets based on label health claims, as the FDA
has only authorized a handful of health claims for dietary supplements. See supra note 259, 260. In contrast, at least 22,500
products bear structure/function claims. See United States General Accounting Office, Food Safety: Improvements
Needed in Overseeing the Safety of Dietary Supplements and \Functional Foods" 21 (July 2000). See also Leticia
M. Diaz, First St. John's Wort, Now SAM-e: Is Society as a Whole at Risk Without FDA Regulation of Psychiatric Self-
Medication, 9 Kansas J.L. & Pub. Pol'y 279 (Winter 1999).
403Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body; Final Rule, 65 Fed. Reg. 1000, 1029 (Jan. 6, 2000).
404United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety of
Dietary Supplements and \Functional Foods" 20 (July 2000). The GAO further criticized that such a claim is \so vague
or general that [it has] little or no scientic meaning and would be very dicult to prove." Id.
405Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,627 (proposed Apr. 29, 1998).
69tive option to the dietary supplement industry. It is advantageous for manufacturers to attempt to \bend"
the structure/function rules as far as possible and to further blur the line between dietary supplements and
drugs. Given the FDA's lackluster enforcement record to date, unscrupulous manufacturers arguably may be
able even to cross the line between allowable structure/function and prohibited disease claims without facing
a signicant risk of regulatory action.406 Accordingly, manufacturers can carefully nuance the wording of
label claims to safely stay within the safe harbor provisions set forth in the DSHEA, while making essentially
drug promises.407 In short, the dietary supplement industry can \suggest[] miracle health benets without
quite promising them,"408 thereby inuencing unsuspecting consumers who see structure/function claims as
implying therapeutic benet.409
The erosion of boundaries between dietary supplements and drugs assumes potentially dangerous implica-
tions, as many consumers rely on supplements as a form of self-treatment for various medical conditions.410 A
variety of factors likely contribute to this trend, including consumer misinterpretation of structure/function
claims as disease claims; manufacturers' eagerness to impute therapeutic benet to boost sales of their prod-
ucts; increasing study and documentation of health benets of supplements; escalating consumer interest
in preventive health measures and self care; and new reliance on alternative therapies due to the growing
406One commentator noted that \the deluge of products { as many as 28,000 currently on the market, according to a government
estimate { has made it much harder for the government to police extravagant claims." Michael Higgins, Hard to Swallow:
While Federal Law Shut the Door on Regulation of Dietary Supplements, Marketing Hype May be Leading the Popular Aids
up Courthouse Steps, 85 A.B.A. J. 60, 60 (June 1999).
407See Roseann B. Termini, Esq., Pharmanex v. Shalala: A Wake Up Call for Congress and a Not So BitterPill for the
FDA, 26 Ohio N.U. L. Rev. 269, 283-84 (2000); Kelly Ann Kaczka, From Herbal Prozac to Mark McGwire's Tonic: How
the Dietary Supplement Health and Education Act Changed the Regulatory Landscape for Health Products, 16 J. Contemp.
Health L. & Pol'y 463, 493 (2000).
408Michael Higgins, Hard to Swallow: While Federal Law Shut the Door on Regulation of Dietary Supplements, Marketing
Hype May be Leading the Popular Aids up Courthouse Steps, 85 A.B.A. J. 60, 62 (June 1999).
409See also United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the
Safety of Dietary Supplements and \Functional Foods" 25 (July 2000) (\[G]iven the signicance of consumer under-
standing of label claims and potential for miscommunication the Commission urged that consumers' understanding of struc-
ture/function and health claims receive continued attention.").
410See, e.g., Michael H. Cohen, U.S. Dietary Supplement Regulation: Belief Systems and Legal Rules, 11 Hastings Women's
L.J. 3, 11-12 (2000); Michele Simon, Still Cloudy, With Little Chance of Clearing: FDA's Proposed Rule on Structure/Function
Claims for Dietary Supplements, 11 Hastings Women's L.J. 23, 25 (2000); Research Firms Suggest Market for Nutraceuticals
is Maturing, 8 Dietary Supplement & Food Labeling News, Sept. 6, 2000, at 19.
70cost of health care.411 As many consumers believe that supplements can help people with illnesses, they are
beginning to shun traditional medical treatment in favor of supplement use.412 Real concerns arise when
consumers move beyond use of supplements for basic nutritional support and maintenance of well-being
but instead rely on unsubstantiated claims and marketing hype to treat more serious conditions. Espe-
cially as many available supplements contain the same ingredients as prescription drugs, the inclination to
self-medicate without physician supervision and to forego routine doctor-patient consultations raises seri-
ous health concerns.413 Further, evidence suggests that consumers are shunning prescribed medication and
instead using supplements to treat such conditions as high blood pressure, diabetes, high cholesterol, and
cancer.414 One survey suggests that consumer self-treatment and use of supplements in place of traditional
medications is becoming widespread, reporting that more than 30 million individuals relied on supplements
instead of over-the-counter (\OTC") drugs and that 19 million additional consumers used both supple-
ments and OTC drugs for therapeutic treatment.415 Arguably, neither Congress nor the FDA intended that
structure/function claims be interpreted as disease claims and used for treatment or prevention purposes,
especially on such a grand scale.416 The FDA explicitly noted that it is important that structure/function
411See Dietary Supplement Health and Education Act of 1994, x 2; Research Firms Suggest Market for Nutraceuticals is
Maturing, 8 Dietary Supplement & Food Labeling News, Sept. 6, 2000, at 19.
412See Laura A.W. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA, 54 Food & Drug L.J. 623,
630-31 (1999).
413See Arnold I. Friede, Dietary Supplements: Background for Dialogue Between the Industry and the Medical Profession, 53
Food & Drug L.J. 413, 419 (1998); Laura A.W. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA,
54 Food & Drug L.J. 623, 629 (1999).
414See Laura A.W. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA, 54 Food & Drug L.J. 623,
629 (1999).
415See Research Firms Suggest Market for Nutraceuticals is Maturing, 8 Dietary Supplement & Food Labeling News,
Sept. 6, 2000, at 19. This study, entitled \The U.S. Market for Vitamins, Supplements, and Minerals," was conducted by
Kalorama Information.
416See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1003 (Jan. 6, 2000); Sen. Rep. No. 103-410, at 17 (1994). Congress
noted in the DSHEA that dietary supplements and good nutrition play a role in \health promotion and disease prevention"
and that \preventive health measures, including ...good nutrition and appropriate use of safe nutritional supplements will
limit the incidence of chronic diseases." Dietary Supplement Health and Education Act of 1994, x 2. The DSHEA further
reects congressional ndings that \there is a denitive link between the ingestion of certain nutrients or dietary supplements
and the prevention of disease." S. Rep. No. 103-410, at 2. These statements, however, do not reect congressional intent to
allow structure/function claims to carry information about disease treatment or prevention. Rather, Congress intended that
the relationship between supplements and disease or health-related conditions be reected as health claims, which are subject
to increased FDA review and scrutiny. See S. Rep. No. 103-410, at 15-17. The requirement that all structure/function claims
bear a disclaimer stating that the \product is not intended to diagnose, treat, cure, or prevent any disease" further supports
71claims \do not promote products for disease treatment or prevention claims," and warned that relying on
such claims for disease treatment \pose[s] serious risks to consumers if they induce consumers to substi-
tute ineective or less eective treatments for proven ones, especially if the disease involved is serious or
life-threatening."417 Several comments to the FDA also added concerns that use of dietary supplements
for treatment purposes, especially absent a physician's supervision, could lead to \potentially harmful drug-
supplement interactions" and create \false hopes" in consumers.418 Not surprisingly, members of the medical
profession are among those critical of the DSHEA.419
Finally, the fairly recent introduction of functional foods into the market has begun to further obfuscate
the distinctions between dietary supplements and food (and hence between drugs and food). Functional
foods, which are regulated by the FDA under the same rules as traditional foods, are products that provide
the basic attributes of food but claim an additional health benet, often obtained through the incorpo-
ration of additional ingredients.420 For example, orange juice is often fortied with calcium and existing
dietary supplements such as echinacea may be added to foods such tea.421 Accordingly, both foods and
dietary supplements may include health claims or structure/function claims on their product labels.422 The
FDA's procedure for health claims is the same for both foods and supplements; claims must be preap-
the assertion that Congress did not intend structure/function claims to be interpreted as disease claims and used for treatment
or prevention purposes. Dietary Supplement Health and Education Act of 1994, 21 U.S.C. x 343(r)(6)(C).
417Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body; Final Rule, 65 Fed. Reg. 1000, 1003 (Jan. 6, 2000). The FDA further noted that the DSHEA, ultimately, bears
responsibility to the extent which truthful, non-misleading information is withheld from structure/function labels, explaining
that section 403(r)(6) of the Act, not the FDA, precluded \unreviewed claims that the product diagnoses, treats, mitigates,
cures, or prevents disease." Id., at 1002-03.
418Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body; Final Rule, 65 Fed. Reg. 1000, 1002 (Jan. 6, 2000).
419See Roseann B. Termini, Esq., Pharmanex v. Shalala: A Wake Up Call for Congress and a Not So Bitter Pill for the
FDA, 26 Ohio N.U. L. Rev. 269, 285 (2000).
420See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 3, 8 (July 2000). Functional foods, dietary supplements, and drugs have
also been collectively dened as \nutriceuticals," indicating that they have a purported nutritive or pharmaceutical health
benet. See Eric F. Greenberg, Food for Thought? Sorting out Consumer Products, Chicago Daily Law Bulletin, March
29, 2000, at 5.
421See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 6 (July 2000).
422See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 3 (July 2000).
72proved through FDA regulation and based on signicant scientic agreement or an authoritative statement.
Structure/function claims for functional foods and dietary supplements, however, are subject to dierent
standards. The primary distinction is that structure/function claims on functional foods do not need to bear
a label disclaimer and are exempt from the notication requirement.423 Therefore, the FDA has no process
to identify those structure/function claims on foods that were poorly substantiated or were unauthorized
drug/disease claims.
As previously discussed, prior to January 2000, the FDA advocated that structure/function claims on sup-
plements were exempt from the disclaimer and notice provisions provided that the claim was \truthful,
nonmisleading, and derived from nutritive value."424 The January 2000 regulations reected an abrupt de-
parture from this earlier position and instead required all dietary supplements to bear a label disclaimer and
to comply with the notication provisions of the DSHEA.425 Subsequently, in February 2000, the FDA's
reversal of position was challenged by three citizen petitions.426 Although the FDA led a notice for com-
ment,427 it has yet to arm or rescind its January 2000 notice and disclaimer rules. Rather, the agency has
merely restated that the mandatory use of disclaimers and notice is based on interpretation of the DSHEA.428
As a result, current FDA regulations regarding disclaimer use for structure/function statements on dietary
supplements and on food products lead to inconsistent, misleading, and inaccurate information to consumers.
First, due to the dierent standards for foods and dietary supplements, a functional food may bear a claim
423See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1033 (Jan. 6, 2000).
424See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1033 (Jan. 6, 2000).
425See Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or
Function of the Body; Final Rule, 65 Fed. Reg. 1000, 1033 (Jan. 6, 2000).
426Nutraceutical Corporation, Petition for Reconsideration and for Stay of Action, No. 98N-0044 (Feb. 4, 2000); American
Herbal Products Association, Petition for Reconsideration and Petition for Stay of Action, No. 98N-0044 (Feb. 7, 2000); Council
for Responsible Nutrition & Consumer Healthcare Products Association, Petition for Reconsideration and Stay of Action, No.
98N-0044 (Feb. 7, 2000).
427See Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function of the
body; Availability of Citizen Petitions for Comment, 65 Fed. Reg. 63,256 (Oct. 23, 2000).
428See Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function of the
body; Availability of Citizen Petitions for Comment, 65 Fed. Reg. 63,256, 63,256 (Oct. 23, 2000).
73unqualied by a disclaimer, while a supplement that derives its structure/function benet from the same
nutrient or ingredient cannot. For example, calcium marketed as a supplement could only bear the statement
\calcium builds strong bones" if it also included a disclaimer that the statement had not been evaluated by
the FDA. If the calcium supplement was added to orange juice, however, the juice could make the claim
absent the disclaimer.429 This disparate treatment over the same nutrient can lead to consumer confusion
regarding the true benets of a product. Arguably, the inconsistency also discriminates against dietary
supplements and implicitly suggests that the claim on the food product is more \deserving" of acceptance
than the claim on the supplement label.430 In addition, the lack of a disclaimer on foods may also imply
that the FDA has evaluated the validity of and authorized the structure/function claim for foods but not for
supplements.431 Finally, requiring manufacturers to provide a disclaimer indicating that the FDA has not
evaluated the structure/function claim on all supplement products may be misleading because the FDA has
evaluated many commonly accepted structure/function claims on supplements, such as the aforementioned
calcium statement.432 Consequently, these inconsistencies are likely to confound \consumers' ability to dis-
tinguish FDA-authorized claims from other claims that have not been reviewed and authorized."433
The regulatory discrepancies regarding structure/function claims in dierent types of products are merely
more obstacles in the path to consumer understanding and informed choices. The diculties inherent in
understanding the distinctions between structure/function claims and health claims, in ascertaining the un-
derlying message of marketing hype and cryptic claim wording, and in successfully using supplements to
complement necessary traditional medicine are confusing enough without the FDA or the DSHEA making
the use of health and structure/function claims inconsistent across product lines.
429See, e.g., CHPA and CRN Press for Nutrient Claims Parity in the USA, Nutraceuticals International (Feb. 1, 2001).
430See Council for Responsible Nutrition & Consumer Healthcare Products Association, Petition for Reconsideration and Stay
of Action, No. 98N-0044, at 6 (Feb. 7, 2000).
431See CHPA and CRN Press for Nutrient Claims Parity in the USA, Nutraceuticals International (Feb. 1, 2001).
432See CHPA and CRN Press for Nutrient Claims Parity in the USA, Nutraceuticals International (Feb. 1, 2001).
433See United States General Accounting Office, Food Safety: Improvements Needed in Overseeing the Safety
of Dietary Supplements and \Functional Foods" 26 (July 2000).
74V.
CONCLUSION
After years of ad hoc regulation of dietary supplements, attempting to strictly curtail access to and claims
attributed to these products, the DSHEA was a positive step. Both Congress and the FDA were hopeful
that it would strike the right balance between ensuring safe, accurate products and information, providing
guidance to the industry, and enabling consumers to be more assertive and proactive in making informed
health choices. Despite these good intentions and the strong public support for the policy changes the
DSHEA suggested, the resulting system fails to fully realize these goals. The resulting consumer confusion
prevents them from making informed health choices; lack of adequate industry guidance and regulation
enforcement has not entirely produced the \rational Federal framework"434 that Congress had envisioned.
Although the situation is not as dire as attempting to cure all health problems with the untested products
of a snake oil salesman, the analogy may still be surprisingly appropriate. Today, consumers continue to rely
on confusing and sometimes overstated product claims of often questionable substantiation; now, however,
many of them are sacricing proven medical treatment in the process.
The problems in the system, however, are not insurmountable. It is also not possible or realistic to hope
to cure all defects and to produce a framework that will satisfy all interests. A solution will likely entail a
combination of a variety of factors, including amended regulations, greater FDA funding, legislative action
434Dietary Supplement Health and Education Act of 1994, x 2.
75to provide more direction, and consumer or physician education. Given the reward of access to safe, accurate
products and information, empowering people to take control of decisions and have better long-term health,
it is worth a bit more eort to tweak the system and make it work as planned.
76